<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Trop Med</journal-id><journal-id journal-id-type="iso-abbrev">J Trop Med</journal-id><journal-id journal-id-type="pmc-domain-id">1196</journal-id><journal-id journal-id-type="pmc-domain">jtm</journal-id><journal-id journal-id-type="publisher-id">jtm</journal-id><journal-title-group><journal-title>Journal of Tropical Medicine</journal-title></journal-title-group><issn pub-type="ppub">1687-9686</issn><issn pub-type="epub">1687-9694</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11703581</article-id><article-id pub-id-type="pmcid-ver">PMC11703581.1</article-id><article-id pub-id-type="pmcaid">11703581</article-id><article-id pub-id-type="pmcaiid">11703581</article-id><article-id pub-id-type="pmid">39764350</article-id><article-id pub-id-type="doi">10.1155/jotm/6688914</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>From Outbreaks to Artificial Intelligence: A Comprehensive Review of Monkeypox Virus Epidemiology, Diagnosis, Treatment, Vaccination, and Deep Learning Applications</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0008-9889-3340</contrib-id><name name-style="western"><surname>Ahmadi</surname><given-names initials="S">Shahed</given-names></name><email>shahedahmadi@sbmu.ac.ir</email><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-7647-6614</contrib-id><name name-style="western"><surname>Amirzadeh</surname><given-names initials="M">Mahdi</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-9694-1514</contrib-id><name name-style="western"><surname>Ahmadi</surname><given-names initials="M">Mousa</given-names></name><xref rid="I2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5641-7380</contrib-id><name name-style="western"><surname>Soleiman-Meigooni</surname><given-names initials="S">Saeed</given-names></name><xref rid="I2" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran</aff><aff id="I2">
<sup>2</sup>Department of Infectious Disease, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran</aff><author-notes><fn fn-type="other"><p>Academic Editor: Wei Wang</p></fn></author-notes><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2024</year></pub-date><volume>2024</volume><issue-id pub-id-type="pmc-issue-id">453361</issue-id><elocation-id>6688914</elocation-id><history><date date-type="received"><day>10</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>12</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>06</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-07 16:25:42.050"><day>07</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 Shahed Ahmadi et al.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JTM2024-6688914.pdf"/><abstract><p>
<bold>Objectives:</bold> After the global impact of the COVID-19 pandemic, concerns over virus transmission have risen. A state of health emergency was declared in 2022 due to Clade 2 of the monkeypox (MPOX) virus. In August 2024, another emergency was declared by the World Health Organization (WHO) because of the widespread Clade 1b, which caused a more severe and lethal disease. This review synthesizes current MPOX knowledge to assist policymakers, clinicians, and researchers in developing effective diagnostics, therapeutic interventions, vaccination strategies, and outbreak management.</p><p>
<bold>Methods:</bold> This systematic review study searched for articles on virus epidemiology, virology, clinical features, transmission routes, available drugs and vaccines, and new artificial intelligence (AI) applications in diagnosis and drug discovery.</p><p>
<bold>Results:</bold> MPOX virus is a 200&#8211;250-nm, double-stranded DNA (ds-DNA) virus that causes smallpox-like skin lesions. Tecovirimat is the primary drug for severe cases, especially in people with suppressed immune systems. Smallpox vaccines can help prevent MPOX infection because of the genetic similarities between the MPOX and smallpox viruses. AI-based models can assist medical teams in promptly diagnosing MPOX skin lesions, improving decision-making for treatment.</p><p>
<bold>Conclusion:</bold> This review highlights the importance of using traditional public health knowledge alongside modern AI to manage MPOX outbreaks effectively. It shows that we need strong public health policies, focused interventions, and ongoing research on how AI can help control infectious diseases.</p></abstract><kwd-group kwd-group-type="Inspec"><title>Keywords</title><kwd>epidemiology</kwd><kwd>monkeypox virus</kwd><kwd>outbreak</kwd><kwd>treatment</kwd><kwd>vaccination</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Monkeypox (MPOX) is a severe and potentially life-threatening zoonotic infectious disease found in Central and West Africa, but it is usually self-limiting [<xref rid="B1" ref-type="bibr">1</xref>]. This tropical viral infectious disease is caused by the family <italic toggle="yes">Poxviridae</italic>, the subfamily <italic toggle="yes">Chordopoxvirinae</italic>, and the genus <italic toggle="yes">Orthopoxvirus</italic>. These are among the largest known DNA viruses, in both size and genetic complexity. Its endemic prevalence in tropical regions, such as Africa, and the characteristics of the pathogen that causes it highlight the tropical and infectious nature of this disease. It has two distinct strains: Clade 1, the Central African strain, which causes a more severe disease with a higher fatality rate, and Clade 2, or the West African strain, which tends to result in a milder illness. After an incubation period of 1&#8211;3&#8201;weeks, nonspecific symptoms such as fever, headache, lymphadenopathy (more typical in MPOX infection), and muscle pain appear, followed by rashes. In the 2022 outbreak, skin lesions were mainly reported in the anogenital region [<xref rid="B2" ref-type="bibr">2</xref>]. It spreads through contact with infected animals, bodily fluids, or contaminated objects. Pregnant women, children, those with an eczema history, and immunocompromised individuals are at higher risk [<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>]. MPOX is diagnosed through polymerase chain reaction (PCR) testing of skin or mucous-membrane samples [<xref rid="B5" ref-type="bibr">5</xref>].</p><p>Treatment for MPOX mainly involves supportive care. Antiviral drugs such as tecovirimat, cidofovir (CDV), and brincidofovir (BCV) are utilized under specific conditions [<xref rid="B6" ref-type="bibr">6</xref>]. Developing new drug delivery systems, such as tecovirimat adsorbed onto carbon microtubes, shows promise for more effective treatment [<xref rid="B7" ref-type="bibr">7</xref>]. Preventive measures are crucial, including avoiding direct contact with infected persons and adhering to strict hygiene and quarantine protocols. Smallpox vaccines provide cross-protection against MPOX due to genetic similarities, while mRNA-based vaccines are being developed for targeted prevention [<xref rid="B8" ref-type="bibr">8</xref>].</p><p>From January to August 2024, over 15,600 MPOX cases and 537 deaths were reported globally, representing a significant public health challenge. The World Health Organization (WHO) attributed this outbreak to the highly virulent Clade 1b strain, associated with severe clinical manifestations and elevated mortality rates. The outbreak primarily affected East, Central, West, and Southern Africa, with high cases reported in Burundi, Kenya, Rwanda, Uganda, the Central African Republic (CAR), Ivory Coast, and South Africa. The rapid spread within these regions highlighted the need for coordinated containment strategies and improved healthcare infrastructure to manage such outbreaks.</p><p>In August 2024, Sweden reported the first case of Clade 1b outside Africa. The case involved an individual who had recently traveled to an affected African region, underscoring the significant role of international travel in the global spread of infectious diseases. This development emphasized the need for policymakers to strengthen border health protocols, implement targeted surveillance measures, and enhance global collaboration to prevent cross-border transmission. The 2024 outbreak has reinforced the importance of integrating travel-related health policies with outbreak management strategies to mitigate the risks of highly transmissible pathogens.</p><p>This review brings together the latest knowledge about MPOX, covering key areas such as its epidemiology, clinical features, diagnostic methods, treatment options, vaccination strategies, and the emerging role of artificial intelligence (AI) in disease management. By combining traditional public health approaches with cutting-edge AI innovations, this review provides valuable insights for policymakers, clinicians, and researchers. It aims to support decision-making, identify research gaps, and enhance preparedness for managing MPOX and similar infectious diseases. This comprehensive perspective contributes to global efforts to control outbreaks and strengthen public health responses.</p></sec><sec id="sec2"><title>2. Method and Material</title><p>Between March and August 2024, we conducted a comprehensive literature search employing advanced search techniques on PubMed, Scopus, and Google Scholar to identify appropriate studies on MPOX. Our priority was on articles published from 2022 onward, while earlier publications were included selectively to provide historical context and foundational information. The search strategy utilized combinations of keywords such as &#8220;monkeypox epidemiology,&#8221; &#8220;clinical features of monkeypox,&#8221; &#8220;PCR monkeypox,&#8221; &#8220;monkeypox treatment options,&#8221; &#8220;monkeypox vaccines,&#8221; and &#8220;artificial intelligence in infectious diseases.&#8221; Boolean operators (AND, OR) were employed to refine results, for instance, &#8220;monkeypox AND (vaccine OR vaccination)&#8221; and &#8220;AI AND monkeypox AND diagnosis.&#8221;</p><p>We defined strict inclusion and exclusion criteria to ensure the quality and relevance of the studies. Peer-reviewed articles, case reports, case series, and studies involving human subjects were included, particularly those addressing epidemiology, clinical manifestations, diagnosis, treatment, vaccination, and AI applications. Non&#8211;peer-reviewed articles, studies focusing exclusively on animal models, articles with insufficient data, and meta-analyses were excluded.</p><p>We adopted a double-masked screening process to minimize selection bias. Two independent reviewers assessed article titles and abstracts. Discrepancies were resolved through discussion or consultation with a third reviewer. Full-text articles were evaluated using a predefined checklist to ensure methodological rigor and relevance. To further reduce bias, a fourth team member reviewed the final selection and data extraction for accuracy. Utilizing multiple databases also ensured the comprehensive coverage of the available literature.</p><p>Data extraction followed a systematic approach, capturing key details such as study design, geographical location, sample characteristics, clinical findings, and significant outcomes. A standardized extraction form was used to maintain uniformity across studies. The findings were synthesized qualitatively to provide a thorough overview of MPOX's epidemiology, clinical features, diagnostic methods, treatment strategies, and AI applications. The flowchart (<xref rid="fig1" ref-type="fig">Figure 1</xref>) clearly outlines the thorough and methodical process we use for selecting articles, ensuring quality and relevance.</p></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. History and Epidemiology</title><p>In 1958, the virus was named MPOX after a new orthopoxvirus outbreak among cynomolgus monkeys in Copenhagen [<xref rid="B9" ref-type="bibr">9</xref>]. The first case of human infection with the MPOX in the Democratic Republic of the Congo (DRC) was observed in 1970 in a 9-month-old boy [<xref rid="B10" ref-type="bibr">10</xref>]. In the 1970s, MPOX outbreaks in the DRC spread through human-to-human transmission and close contact with infected animals during the hunts in warm seasons and hunting areas [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. The increase in human-to-human transmission raises apprehensions about the potential for widespread zoonotic disease. As a result, between 1981 and 1986, the WHO reported 338 suspected cases of the disease and 33 deaths through the implementation of surveillance programs [<xref rid="B12" ref-type="bibr">12</xref>]. Subsequently, positive cases decreased dramatically over the following six years, with only 13 cases registered in Cameroon, Gabon, and the DRC from 1986 to 1992 [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. Kasa&#239;-Oriental Province in the DRC was the site of the next major outbreak two years following 1992, with 511 suspected cases in the Katako-Kumba region and 24 in the Lodja health zone [<xref rid="B13" ref-type="bibr">13</xref>&#8211;<xref rid="B16" ref-type="bibr">16</xref>]. Between 1998 and 2001, the DRC and CAR experienced an ongoing MPOX outbreak, during which the Ministry of Health of DRC documented 1265 cases over the three years [<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>]. In 2003, the United States reported the first human cases of MPOX outside Africa, with 72 instances of Clade 2 MPOX, with a median age of 28&#8201;years traced back to prairie dogs that had been infected by rodents transported from Ghana to Texas [<xref rid="B19" ref-type="bibr">19</xref>]. From September to December 2005, cases spread in Sudan's Unity State, with 760 cases reported across nine locations in Congo by 2007 [<xref rid="B12" ref-type="bibr">12</xref>]. No outbreaks occurred outside Africa until 2021. In Africa, outbreaks were reported in the DRC, Sierra Leone, and CAR between 2010 and 2016. These included a small outbreak in the Likouala region of the DRC, an outbreak in Bo City, Sierra Leone, and reported cases in Bangassou, in CAR. A more widespread outbreak occurred in the DRC between 2014 and 2016, with 587 suspected cases detected during the country's surveillance program [<xref rid="B18" ref-type="bibr">18</xref>]. The largest outbreak of MPOX in West Africa occurred between 2017 and 2018, with 244 cases following the infection of an 11-year-old child in Nigeria [<xref rid="B12" ref-type="bibr">12</xref>]. The travel of suspected cases of Clade 2 from Nigeria to the United Kingdom and Israel caused the 2018 outbreak in these two countries [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>]. In July 2021, a middle-aged American man with a history of traveling to Nigeria was reported as an infection-positive case in the United States [<xref rid="B19" ref-type="bibr">19</xref>]. As vaccination against smallpox declined, global immunity to orthopoxviruses also decreased. In March 2022, while the world was still grappling with COVID-19, six confirmed cases of MPOX and two deaths were reported in the CAR. From the beginning of 2022 until April 17, the DRC registered 1152 suspected cases with 55 deaths [<xref rid="B19" ref-type="bibr">19</xref>].</p><p>In 2022, a major global outbreak of MPOX occurred as the infection spread from Africa to Europe and America. The majority of cases were among men who have sex with men (MSM) [<xref rid="B22" ref-type="bibr">22</xref>], many of whom had not traveled to areas where the disease is endemic. It is vital to clarify the epidemiological links between instances in different regions and the role of asymptomatic in spreading the virus [<xref rid="B12" ref-type="bibr">12</xref>].</p><p>Comparatively to 2022, the practically steady and declining trend of obtaining this virus in Africa in 2023 is seen. Between the start of 2024 and the writing of this article in August, there have been more than 15,600 positive cases with 537 deaths. Unlike the 2022 outbreak with Clade 2, the WHO has linked this new outbreak in the DRC to the more lethal strain of the virus, Clade 1b, to neighboring nations [<xref rid="B23" ref-type="bibr">23</xref>]. The new outbreak began in July of this year and is currently affecting East, Central, West, and South Africa. The nations that reported positive cases of the new disease in the most recent outbreak were Burundi, Kenya, Rwanda, and Uganda in East Africa; the CAR in Central Africa; Ivory Coast in West Africa; and South Africa [<xref rid="B24" ref-type="bibr">24</xref>]. On August 14, 2024, the WHO again issued a public health emergency due to the general spread of the most current strain [<xref rid="B23" ref-type="bibr">23</xref>]. The clade has quickly spread to countries outside Africa, marking a significant global impact. On August 15, 2024, Sweden became the first nation outside of Africa to record a positive case of the hazardous clade of MPOX in someone who had recently resided in Africa [<xref rid="B25" ref-type="bibr">25</xref>]. Pakistan [<xref rid="B26" ref-type="bibr">26</xref>]and the Philippines [<xref rid="B27" ref-type="bibr">27</xref>] also announced new positive cases of the Clade 1b following Sweden's case.</p></sec><sec id="sec3.2"><title>3.2. Virology</title><p>The MPOX virus is a double-stranded DNA (ds-DNA) virus belonging to the <italic toggle="yes">Poxviridae</italic> family and genus <italic toggle="yes">Orthopoxviruses</italic>. Its vast persistence in the zoonotic cycle and diverse range of hosts set it apart from other members of this family (e.g., cowpox, variola virus, and smallpox) [<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>]. It was known by this name since 1958 after infecting cynomolgus monkeys [<xref rid="B9" ref-type="bibr">9</xref>]. There are now two different clades of the MPOX virus. Clade 1 is the leading cause of MPOX infections in Central Africa and the Congo Basin [<xref rid="B30" ref-type="bibr">30</xref>&#8211;<xref rid="B32" ref-type="bibr">32</xref>], with a case-fatality rate ranging from 1% to 12% [<xref rid="B33" ref-type="bibr">33</xref>]. Conversely, the most common strain in West Africa is Clade 2, which has a much lower case-fatality rate of about 0.1% [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>]. The 2022 global outbreak of MPOX was similarly linked to Clade 2 [<xref rid="B36" ref-type="bibr">36</xref>], which exhibited distinct severity and clinical manifestations when compared to Clade 1. The differences in case-fatality rates and infection severity between these two clades are caused by a slight genetic variance of around 0.5% in their genomic sequences [<xref rid="B30" ref-type="bibr">30</xref>]. Host&#8211;response modifier (HRM) genes, such as the complement pathway inhibitor enzyme gene (PICE or MOPICE), exhibit diversity among the clades of the MPOX virus, contributing to the differences between them [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B37" ref-type="bibr">37</xref>]. As suggested by animal studies, the absence of this gene in Clade 2 is responsible for the lower case-fatality rate observed in this clade [<xref rid="B38" ref-type="bibr">38</xref>]. The B.1 lineage, a subgroup of Clade 2b (known as Clade 3), was responsible for the 2022 global outbreak, and the only reported case of MPOX in Iran (Khuzestan) was infected with this lineage [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B39" ref-type="bibr">39</xref>]. The MPOX genome is a 197-kilobase pair ds-DNA linear genome with inverted terminal repeats (ITRs) at both ends. It encodes approximately 200 proteins essential for viral particle formation, DNA replication, and completing the viral structure within the host cell [<xref rid="B33" ref-type="bibr">33</xref>]. The MPOX virus has a brick-shaped structure measuring 200&#8211;250&#8201;nm. Its surface is covered in tubular filaments, and a biconcave core houses the viral genome, similar to those of variola and vaccinia viruses.</p></sec><sec id="sec3.3"><title>3.3. Diagnose</title><p>Diagnosing MPOX without clinical testing is especially important in low-resource settings where access to healthcare facilities and laboratory tests is limited. Recognizing key symptoms, such as fever, headache, muscle aches, back pain, swollen lymph nodes, and a distinctive rash that progresses through various stages, can help identify the disease early. This approach can reduce the financial burden on families and ensure timely care. Social and environmental factors play a major role in the spread of MPOX. In regions where the disease is common, such as parts of Africa, people often live in close contact with wildlife, increasing the risk of catching the virus. Activities like hunting and eating bushmeat expose individuals to infected animals, such as rodents and primates, which are the primary carriers of the virus. Communities living near forests or rural areas where these animals are common face a higher risk of infection. Poor living conditions, such as lack of clean water, overcrowded homes, and limited access to healthcare, make it easier for the disease to spread within families and neighborhoods. Migration, travel, and large gatherings also contribute to the virus moving into new areas. Raising awareness about these risks, encouraging preventive actions, and training healthcare workers to identify symptoms can make a big difference in controlling MPOX outbreaks and protecting vulnerable communities.</p><sec id="sec3.3.1"><title>3.3.1. Laboratory Diagnosis</title><p>As advised by the WHO, other potential diagnoses such as syphilis, Orf, mycosis, and drug sensitivity reactions should also be considered in the diagnosis of MPOX infection [<xref rid="B40" ref-type="bibr">40</xref>]. Real-time PCR (RT-PCR) is the most crucial test for virus detection, with laboratory guidelines recommending the targeting of at least two common genes among different strains of the disease. This adaptability is evident in the targeting of genes such as the TNF receptor gene, <italic toggle="yes">E9L</italic> DNA polymerase gene [<xref rid="B41" ref-type="bibr">41</xref>], <italic toggle="yes">B6R</italic> envelope protein gene [<xref rid="B42" ref-type="bibr">42</xref>], and DNA-dependent RNA polymerase gene [<xref rid="B40" ref-type="bibr">40</xref>], along with proposed target proteins including polymerase subunit 18, <italic toggle="yes">B7R</italic> [<xref rid="B43" ref-type="bibr">43</xref>], <italic toggle="yes">FL3</italic> [<xref rid="B43" ref-type="bibr">43</xref>], <italic toggle="yes">N3R</italic> [<xref rid="B40" ref-type="bibr">40</xref>], <italic toggle="yes">C3L</italic> complement-binding protein [<xref rid="B40" ref-type="bibr">40</xref>], <italic toggle="yes">CP</italic> protein gene [<xref rid="B44" ref-type="bibr">44</xref>], and <italic toggle="yes">O2L</italic> gene [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B45" ref-type="bibr">45</xref>]. Other less common identification methods include electron microscopy following staining to identify the virus in lesion samples [<xref rid="B46" ref-type="bibr">46</xref>] and detecting specific viral antigens through immunohistochemistrical methods [<xref rid="B47" ref-type="bibr">47</xref>].</p><p>Because the virus proliferates in mammalian cell lines, including HeLa, Vero, BSC-1, and RK-13, virus culture using these cell lines is one of the more established diagnostic methods [<xref rid="B48" ref-type="bibr">48</xref>]. Diagnosing MPOX with specific serological tests is challenging due to potential cross-reactivity with other orthopoxviruses. Assessing (acute immunoglobulin) IgM in the first week or (late immunoglobulin) IgG in paired samples 21&#8201;days apart can significantly impact patient care and aid in diagnosis [<xref rid="B49" ref-type="bibr">49</xref>].</p></sec></sec><sec id="sec3.4"><title>3.4. Incubation Period</title><p>According to reports from the 2022 MPOX outbreak, the illness typically takes 5 to 13 days to incubate [<xref rid="B50" ref-type="bibr">50</xref>]. However, the length of time has varied depending on the region. The incubation period ranged from 6.5 to 10.9&#8201;days (with a 95% confidence interval [CI]; average 9.1&#8201;days) among patients tested in Italy in May and June of 2022 [<xref rid="B51" ref-type="bibr">51</xref>]. Compared to the 2005 outbreak in the United States, which lasted between 11 and 18&#8201;days, it seems that the incubation time for MPOX infections in 2022 has changed [<xref rid="B52" ref-type="bibr">52</xref>]. Furthermore, several factors affect the incubation period, like the infection route. For instance, compared to infection through sexual contact, the incubation time is shortened by being bitten or scratched [<xref rid="B53" ref-type="bibr">53</xref>]. Additionally, some reports indicate that this period can extend to 21&#8201;days [<xref rid="B54" ref-type="bibr">54</xref>].</p></sec><sec id="sec3.5"><title>3.5. Pathogenesis</title><p>The method of virus entry (via the respiratory system or the skin) and the specific clade of MPOX can affect the clinical manifestation of infection. The virus begins reproducing after it invades the host's respiratory system and mucous membranes in the throat and mouth through the respiratory route. Likewise, after exposure to MPOX in the dermis, keratinocytes, fibroblasts, and endothelial cells can undergo this process [<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>]. Immunohistochemistry of skin lesion biopsies can reveal intraepidermal, intrafollicular, intravascular, interstitial, and perivascular neutrophils (MPO), T-cell infiltrates (CD3), cytotoxic T cells (CD4 and CD8), and macrophages (CD68) [<xref rid="B47" ref-type="bibr">47</xref>]. The pathophysiology of MPOX infection drafts two viremias. During primary viremia, the virus replicates at the site of infection and spreads to the lymph nodes, leading to submandibular, cervical, or inguinal lymphadenopathy. After secondary viremia, the virus disseminates to organs through the bloodstream [<xref rid="B57" ref-type="bibr">57</xref>]. The virus variant significantly affects disease manifestation. In Clade 1 of MPOX, the virus replicates in the respiratory epithelium during the incubation period before spreading to lymphoid organs such as the spleen and liver and then can be detected in the blood after the incubation period [<xref rid="B58" ref-type="bibr">58</xref>&#8211;<xref rid="B60" ref-type="bibr">60</xref>]. But primate models, infected by Clade 2, exhibited that the replication of virus befalls in just cutaneous and lymphoid system [<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B60" ref-type="bibr">60</xref>]. This is why the clade of MPOX has higher pathogenicity. The replication cycle of the MPOX virus begins with the virus entering the host cell via micropinocytosis or direct fusion with the plasma membrane. Crucial for the attachment of the virion are key components such as exterior virion proteins, surface glycosaminoglycans, and extracellular matrix elements [<xref rid="B61" ref-type="bibr">61</xref>]. Upon entry, the virus damages its outer membrane, releasing its core into the cytoplasm for uncoating. Early gene expression generates essential early proteins, such as intermediate transcription factors, DNA polymerase, and RNA polymerase, required for viral replication and immune response control. The virus's DNA replicates within specialized areas of the cytoplasm, producing multiple copies of the viral genome. The virus synthesizes the intermediate proteins and late transcription factors to produce immature virions (IVs) and then mature to become mature virions (MVs). The Golgi apparatus transports some MVs, envelops them, and transforms them into wrapped virions (WVs). WV is carried to the cell's outside edge, either discharged as extracellular virions (EVs) or remained as cell-associated enveloped virions (CEVs) for cell transmission. Cell lysis can also release MVs, facilitating their transfer from one host to another. This process facilitates effective duplication and dissemination, resulting in observable clinical manifestations such as skin rash and swelling of the lymph nodes [<xref rid="B62" ref-type="bibr">62</xref>]. <xref rid="fig2" ref-type="fig"> Figure 2</xref> illustrates this process in detail, providing a more precise understanding.</p></sec><sec id="sec3.6"><title>3.6. Immune Response</title><p>The immune response to human MPOX infection involves both innate and adaptive immunity [<xref rid="B63" ref-type="bibr">63</xref>]. The innate immune system is triggered in response to viral infections. This activation occurs mainly through the release of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-<italic toggle="yes">&#945;</italic>), interleukin-1 (IL-1), and interferons (INFs) by dendritic cells, natural killer cells, and macrophages. These cytokines serve to signal and attract more immune cells to the site of infection. This coordinated immune response aims to contain and eliminate the pathogen, ensuring a thorough and efficient defense [<xref rid="B64" ref-type="bibr">64</xref>]. Both CD4+ (helper T cells) and CD8+ cytotoxic T cells are activated by MHC Class I antigens from macrophages and dendritic cells. CD4&#8201;T cells help B cells become plasma cells that secrete antibodies. CD8+ T cells activated by interleukins, granzyme B, and perforin become more cytotoxic. This synchronized response kills virus-infected cells and provides a strong resistance against viral infections [<xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B66" ref-type="bibr">66</xref>]. Toll-like receptors (TLRs), NOD-like receptors (NLRs), C-type lectin receptors (CLRs), and RIG-1-like receptors (RLPs) are pattern recognition receptors (PRPs) that play a crucial role in the innate immune system. They are responsible for identifying a wide range of molecules associated with damaged cells [<xref rid="B67" ref-type="bibr">67</xref>]. Upon the activation of PRPs, a series of processes are initiated, resulting in the activation of transcription factors associated with inflammation, such as nuclear factor-kappa B (NF-<italic toggle="yes">&#954;</italic>B) and INF regulatory factors (IRFs) [<xref rid="B68" ref-type="bibr">68</xref>]. On the other hand, the virus has effective ways to dodge the immune system. A47R is a protein produced by MPOX that can interact with intracellular adaptors of TLRs and suppress the upregulation of NF-<italic toggle="yes">&#954;</italic>B expression, which leads to the inhibition of apoptosis regulating via interaction with the I<italic toggle="yes">&#954;</italic>B kinase (IKK) complex that is necessary for the activation of NF-<italic toggle="yes">&#954;</italic>B and has a critical role in control of programmed cell death [<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>]. MPOX employs soluble cytokines to evade the immune system. These cytokines competitively bind to the immune system's cytokines, hindering the expression of antiviral genes and facilitating viral replication. This is achieved by disrupting the activated downstream signaling pathway when cytokine receptors are occupied. Additionally, MPOX downregulates the expression of MHC-1 on infected cells and secretes proteins that can target immune molecules such as IL-1<italic toggle="yes">&#946;</italic>, IL8, CCL5, and CCL2. While both Clade 1 and Clade 2 of MPOX can produce proteins that mimic Bcl-2 proteins, which play a crucial role in regulating apoptosis, the Zaire-I-96 strain of MPOX can encode a protein called P1L that can modulate the apoptosis pathway similar to Bcl-2 [<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B70" ref-type="bibr">70</xref>].</p></sec><sec id="sec3.7"><title>3.7. Transmission</title><p>Mostly by animal-to-human transmission, direct human-to-human transmission through close contact, and indirect human-to-human transmission.</p><sec id="sec3.7.1"><title>3.7.1. Animal-to-Human Transmission</title><p>Until the outbreak of MPOX in 2022, most of the studies were on direct or indirect transmission from infected animals to humans. Besides infecting via direct contact with infected animals, the transmission of the infection through respiratory fluids, fomites, and consumption of infected meats is prominent in the disease [<xref rid="B71" ref-type="bibr">71</xref>]. While it is not definitively established that rodents are the main reservoir of MPOX infection, humans are regarded as incidental hosts in the natural environment. In 1964, American giant anteaters (<italic toggle="yes">Myrmecophaga tridactyla</italic>) at the Rotterdam Zoo were infected, most likely due to contact with monkeys [<xref rid="B72" ref-type="bibr">72</xref>]. In a 1980 study of 338 MPOX patients (most of them were below 15&#8201;years old), over 72% of cases in the DRC were linked to animal interactions [<xref rid="B73" ref-type="bibr">73</xref>]. In 2003, unexpected events occurred when exotic rats from Ghana, sold as pets, entered the American pet trade. The virus then spread to prairie dogs, leading to human outbreaks as people came in contact with sick animals and their fluids. This transmission occurred primarily through respiratory droplets and saliva [<xref rid="B61" ref-type="bibr">61</xref>]. In several African countries, lifestyles include forest living, hunting, bushmeat handling, and even animal's cage cleaning (noninvasive exposure) and infected animal biting (invasive exposure), which greatly increase the likelihood of animal-to-human transmission of MPOX [<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B74" ref-type="bibr">74</xref>]. These activities increase human&#8211;wildlife interaction, therefore increasing exposure to possible animal reservoirs and vectors and helping infectious diseases to spread.</p></sec><sec id="sec3.7.2"><title>3.7.2. Human-to-Human Transmission</title><p>Unlike animal-to-human infection, human-to-human (especially transmitted by respiratory droplets) has a low transmission rate. All 57 healthcare professionals who came into unprotected contact with MPOX in a 2005 cohort study stayed asymptomatic over the observation period [<xref rid="B75" ref-type="bibr">75</xref>]. Aside from the possibility of infection spreading through contact with contaminated objects or using the same serving dish as an infected person, direct exposure to respiratory droplets, extended face-to-face interaction, physical contact with affected skin areas, and sexual contact are significant routs of transmitting MPOX between humans [<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B61" ref-type="bibr">61</xref>]. In the 2022 outbreak, the primary mode of human-to-human transmission appears to be through sexual contact. A study in Portugal included 47 male participants, 39 of whom were recognized as MSM. Likewise, six individuals reported engaging in sexual activity with more than ten [<xref rid="B76" ref-type="bibr">76</xref>]. In another 2022 observational cohort study that carried out in Bichat&#8211;Claude Bernard University Hospital in Paris on 264 patients, 245/295 (95%) of them were men engaged in sexual activities with other men [<xref rid="B77" ref-type="bibr">77</xref>].</p></sec></sec><sec id="sec3.8"><title>3.8. Clinical Manifestations</title><p>After an asymptomatic latent period of approximately 8&#8201;days, individuals infected with MPOX exhibit nonspecific prodromal symptoms. These early signs, which precede the characteristic skin lesions, include fever (between 38.5&#176;&#8201;C and 40.5&#176;C), pruritus, and swollen painful lymph nodes (1&#8211;4&#8201;cm in diameter) in the submandibular, cervical, and inguinal regions&#8212;crucial for differentiating MPOX from smallpox or chickenpox. Typical symptoms within a 95% CI are fatigue, sore throat, difficulty swallowing, headache, backache, cough, photophobia, shortness of breath, nausea, vomiting, and diarrhea [<xref rid="B78" ref-type="bibr">78</xref>&#8211;<xref rid="B82" ref-type="bibr">82</xref>]. Skin lesions, usually 5&#8211;10&#8201;mm in size, start on the trunk and face and spread centrifugally to peripheral organs such as the palms and soles about 1&#8211;3&#8201;days after the prodromal phase. They progress from macular rashes to maculopapular, vesicular, and pustular stages and form crusts and scabs within one to two weeks. Lymphadenopathy remains due to the virus's strong immune response [<xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>]. A thorough assessment examining cases before and after the 2022 outbreak found that more than 100 lesions were observed in almost 50% of the patients [<xref rid="B79" ref-type="bibr">79</xref>]. Simultaneously with the emergence of skin lesions, lesions also arise in the oral and vaginal regions [<xref rid="B85" ref-type="bibr">85</xref>]. It is advised to practice isolation during the initial week of the rash, as the patient is considered contagious until the scabs separate and the throat swab PCR findings show no signs of infection [<xref rid="B14" ref-type="bibr">14</xref>]. Immunocompromised and pregnant individuals are more prone to experiencing complications of the condition. These complications include secondary bacterial soft tissue infection, hemorrhagic pustules, pneumonia, and encephalitis [<xref rid="B86" ref-type="bibr">86</xref>]. MPOX can be passed from mother to fetus during delivery in pregnant women, potentially resulting in spontaneous miscarriage occurring 14&#8211;24&#8201;days after the onset of fever. A stillborn fetus may display maculopapular lesions, hepatomegaly, and hydrops fetalis. Postnatal transmission can also happen through close contact while breastfeeding, comparable to the transmission of varicella zoster and Herpes Simplex viruses [<xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B88" ref-type="bibr">88</xref>]. However, the clinical manifestations differed slightly during the 2022 outbreak. Several cases exhibited a solitary cutaneous lesion, predominantly localized in the anogenital region (as indicated in the table), and frequently initiated its development in that area. The lesions were frequently characterized by discomfort and did not exhibit the previously reported tendency to spread to other locations. More research is needed to understand the increased sexual transmission of Clade 2 of the virus and its genetic characteristics. Furthermore, in certain instances, cutaneous lesions manifested prior to the commencement of fever [<xref rid="B89" ref-type="bibr">89</xref>]. Nevertheless, a significant majority of participants (over 60%) in a cohort study conducted in Spain experienced systemic symptoms before the appearance of a rash [<xref rid="B90" ref-type="bibr">90</xref>]. As summarized in <xref rid="tab1" ref-type="table">Table 1</xref>, fever was reported in 53%&#8211;72% of patients across different studies, with lymph node swelling being a notable feature in 29%&#8211;85% of cases, distinguishing MPOX from other orthopoxvirus infections. Skin lesions displayed a significant regional variation. Genital lesions were the most common, affecting up to 75% of patients in Spain, Portugal, and Canada, as noted by Tarin-Vicente et al. [<xref rid="B90" ref-type="bibr">90</xref>] and Sousa et al. [<xref rid="B76" ref-type="bibr">76</xref>]. In the United Kingdom and Germany, facial and trunk lesions were more prevalent, with rates between 20% and 55%. These differences highlight the need for tailored diagnostic approaches. <xref rid="tab1" ref-type="table">Table 1</xref> shows that affected individuals typically have a median age of 35&#8211;42&#8201;years, with a notable prevalence among MSM in urban areas. Additionally, HIV coinfection rates ranged from 21% to 47%, indicating a need for integrated care for high-risk populations</p></sec><sec id="sec3.9"><title>3.9. Complications</title><p>MPOX infections can lead to both neurological and psychosocial consequences. According to a Nigerian study conducted in 2020, 25% of patients who were admitted to the hospital exhibited psychiatric symptoms, including anxiety, despair, low mood, and suicidal thoughts [<xref rid="B107" ref-type="bibr">107</xref>]. Distinguishing these psychological symptoms from those caused by hospitalization and quarantine presents a considerable challenge. Neurological issues such as seizures, disorientation, and encephalitis have been seen in individuals with MPOX during the 2022 outbreak, with prevalence rates of 2.7%, 2.4%, and 2, respectively [<xref rid="B108" ref-type="bibr">108</xref>]. Moreover, brain magnetic resonance imaging (MRI) scans of patients with acute disseminated encephalomyelitis (ADEM) who have received vaccinations reveal normal levels of viruses and detectable specific MPOX IgM antibodies in the analysis of cerebrospinal fluid (CSF) (94&#8211;96). During the 2022 outbreak in the United States, two individuals with weakened immune systems developed encephalomyelitis 5&#8211;9&#8201;days after experiencing initial symptoms [<xref rid="B109" ref-type="bibr">109</xref>]. In the cases of systemic MPOX infection, the lack of viral nucleic acid in the CSF, elevated CSF protein levels, and pleocytosis indicate autoimmune responses rather than viral invasion. MRI scans showed brain and spinal lesions in Patients 1 and 2, which suggests MPOX-related proctitis in Patient 2 [<xref rid="B109" ref-type="bibr">109</xref>].</p><p>MPOX virus causes ocular symptoms in unvaccinated and immunosuppressed people. Eye rashes (14.37%), conjunctivitis (13.89%), redness, discomfort, and discharge (26.9%), conjunctival ulceration (2.13%), lesions (1.62%), and eyelid pustules and pseudopustules (1.08%) are given by pooled prevalence [<xref rid="B110" ref-type="bibr">110</xref>].</p><p>Severe infections can lead to complications such as myocarditis, epiglottitis, peritonsillar abscess, rectal wall rupture, hemophagocytic lymphohistiocytosis, bronchopneumonia, and necrotizing pneumonia [<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B103" ref-type="bibr">103</xref>, <xref rid="B111" ref-type="bibr">111</xref>]. The immune response to viral fragments impacting the myocardium can cause myocarditis or pericarditis [<xref rid="B112" ref-type="bibr">112</xref>]. This phenomenon can also be observed following the administration of the smallpox vaccine [<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B114" ref-type="bibr">114</xref>]. A review study conducted in 2023 on myocarditis caused by MPOX infection found that all cases of myocarditis were accompanied by chest pain and difficulty breathing. Electrocardiographic tests showed ST-elevation in 44% of patients and sinus tachycardia in 22% of patients. Echocardiographic findings indicated a decrease in the ejection fraction in 43% of patients, with an average ejection fraction of 52.14%. Cardiac magnetic resonance (CMR) imaging revealed gadolinium enhancement and edema in 40% of the cases examined [<xref rid="B115" ref-type="bibr">115</xref>]. There have been reports of bronchopneumonia and necrotizing pneumonia in humans infected with MPOX. One case involved a 36-year-old man who had HIV, tertiary syphilis, cryptosporidiosis, and Kaposi's sarcoma. Chest radiography showed progressive bilateral nodules, and he developed necrotizing pneumonia as a result of the MPOX infection. Unfortunately, he died from pseudomonas sepsis on the 28th day of the infection [<xref rid="B111" ref-type="bibr">111</xref>]. The ICU admission of a 34-year-old Caucasian French woman revealed the presence of acute respiratory distress syndrome, characterized by symptoms such as fever, hypotension, decreased oxygen saturation, and mental abnormalities. The PCR test confirmed that she was infected with MPOX, and the culture of her pleural fluid showed the presence of Streptococcus pyogenes. The high-resolution computed tomography (CT) scans showed significant bilateral consolidation in this case [<xref rid="B116" ref-type="bibr">116</xref>].</p></sec><sec id="sec3.10"><title>3.10. Treatment</title><p>Given the self-limiting nature of MPOX in most cases, conventional antiviral treatment is often unnecessary since many patients can recover with supportive care alone. To reduce the risk of drug resistance and ensure the effectiveness of antiviral drugs, it is essential to limit their use to severe cases or patients at high risk of serious consequences and death, such as those with weakened immune systems due to HIV or chemotherapy with alkylating drugs.</p><p>Supportive care management: Behavior, local, and systemic treatments are used to cure MPOX. Avoid contact lenses, use trifluridine or mineral oils on the eyes for pain and lubrication, apply lidocaine gel to moderate skin lesions, and use a cream with amitriptyline 2%, ketamine 5%, and baclofen 5% for painful anogenital lesions. NSAIDs are also given systemically to ease pain [<xref rid="B117" ref-type="bibr">117</xref>]. It is advised to cover MPOX cutaneous lesions to stop the disease from spreading directly through them and to gently wash them with soap and water in order to treat MPOX dermal lesions optimally. Patients should also avoid scratching lesions to prevent infection and spread.</p><p>Antiviral treatment: The lack of specific antiviral MPOX drugs necessitates using tecovirimat and CDV, which were initially approved for other uses. Understanding the virus's structure and critical proteins is crucial for developing targeted antiviral therapies.</p><p>Tecovirimat (ST-246), also known as TPOXX&#174;, is an antiviral medication specifically developed to inhibit the VP37 protein, which is produced by the F13L gene. This gene is responsible for conferring resistance to BCV in orthopoxviruses, including vaccinia and MPOX. This protein is crucial for creating extracellular enveloped virions (EEVs) by assisting in encasing intracellular MVs (IMVs) with the lipid membrane of the host cell. Tecovirimat inhibits the development of MVs that can leave the cell and disseminate the virus by binding to VP37 and blocking its interactions with GTPase, Rab9, and TIP47, thus restricting the infection [<xref rid="B118" ref-type="bibr">118</xref>]. This antiviral medication was authorized by the FDA in 2018. It is offered in two dosage forms: a 600-mg oral capsule taken twice a day and a 200-mg intravenous infusion also taken twice a day. This treatment is the principal treatment for severe instances of MPOX and individuals at high risk of severe disease, such as those with a weakened immune system and asplenia, or who are receiving alkylating drugs. Significantly, the oral formulation demonstrates increased absorption when consumed with food in a fed condition [<xref rid="B119" ref-type="bibr">119</xref>]. However, the efficacy of this drug can be compromised by resistance due to a mutation at Amino Acid Position 277 [<xref rid="B120" ref-type="bibr">120</xref>]. In a 2023 report, 84.6% of patients receiving tecovirimat intravenously experienced at least one adverse effect. The most common were pain at the infusion site (73.1%), swelling (38.5%), and erythema (23.1%). Headaches and dizziness were also reported by 26.9% and 23% of patients, respectively. Other side effects such as myalgia, back pain, diarrhea, and photophobia were rare, occurring in less than 5% of cases [<xref rid="B121" ref-type="bibr">121</xref>]. No renal dose adjustment needed in the capsule formulation of tecovirimat, while its IV formulation is contraindicated in CrCl below 30&#8201;mL/min due to B-cyclodextrin existence in formulation [<xref rid="B122" ref-type="bibr">122</xref>]. Prairie dogs, macaque monkeys, and cynomolgus monkeys (<italic toggle="yes">Macaca fascicularis</italic>) are the examples of tecovirimat's therapeutic applications [<xref rid="B123" ref-type="bibr">123</xref>&#8211;<xref rid="B126" ref-type="bibr">126</xref>]. In a 2011 study, Prairie dogs (<italic toggle="yes">Cynomys ludovicianus</italic>) infected with the Congo basin clade were administered intranasally with tecovirimat, and it was celebrated that 100% of cases improved and became asymptomatic without any instances of death [<xref rid="B125" ref-type="bibr">125</xref>]. Before that, in a 2009 study, intravenous administration of tecovirimat at a dose of 3&#8201;mg/kg/day, three days postinfection, established a zero percent mortality rate in cynomolgus monkeys infected with the West African clade [<xref rid="B126" ref-type="bibr">126</xref>]. It is also worth mentioning that there are no reports of fetal toxicity regarding this medicine [<xref rid="B122" ref-type="bibr">122</xref>].</p><p>CDV (VISTIDE&#174;), also known by its IUPAC designation [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid, is a pharmaceutical compound that acts as a cytosine nucleotide analog and inhibits the activity of DNA polymerase. It has been granted approval by the FDA for the treatment of cytomegalovirus (CMV) retinitis in individuals who are infected with HIV [<xref rid="B127" ref-type="bibr">127</xref>]. Upon cellular uptake, CDV undergoes phosphorylation by the host cell's enzyme, resulting in the formation of CDV diphosphate (CDV-pp), which is its active form. This active form affects the elongation of the DNA chain during replication by competitively limiting the inclusion of deoxycytidine triphosphate [<xref rid="B128" ref-type="bibr">128</xref>]. Due to inadequate absorption in the gastrointestinal (GI) tract, pharmacists were compelled to produce an intravenous dosage form with a recommended dose of 5&#8201;mg/kg once weekly for the treatment of MPOX infection [<xref rid="B129" ref-type="bibr">129</xref>]. The most significant adverse effect of CDV is nephrotoxicity, which is dose-dependent. This is characterized by the presence of proteinuria followed by glucosuria, an increase in the blood creatinine level, and a decrease in the serum bicarbonate concentration [<xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B130" ref-type="bibr">130</xref>]. Additional documented adverse effects comprise neutropenia, ocular hypotony, iritis, uveitis, and pyrexia [<xref rid="B130" ref-type="bibr">130</xref>]. Misuse of different antimicrobial medications may lead to the development of drug-resistant strains in the same group of microorganisms. The susceptibility of the MPOX virus to resistance is a significant trouble. The emergence of CDV-resistant species among orthopoxviruses, including MPOX, complicates the situation further [<xref rid="B131" ref-type="bibr">131</xref>]. The rise of CDV-resistant orthopoxviruses, such as smallpox, vaccinia, and MPOX, presents a major health risk due to specific mutations found in the <italic toggle="yes">E9L</italic> (DNA polymerase) and <italic toggle="yes">F13L</italic> (viral membrane protein) genes of vaccinia virus. Similar genetic variations, specifically <italic toggle="yes">A314V</italic> and <italic toggle="yes">A684T</italic>, have also been observed in MPOX virus. These genetic changes result in reduced ability to cause disease and replicate efficiently, requiring ongoing monitoring of the genome, the creation of different treatment options, and additional investigation into the specific molecular processes and adaptability of resistant strains [<xref rid="B132" ref-type="bibr">132</xref>, <xref rid="B133" ref-type="bibr">133</xref>].</p><p>In 2021, the FDA-approved BCV (marketed as Tembexa&#174;) for treating smallpox. This medication enhances the lipophilicity and cellular permeability of CDV by including a hexadecyloxypropyl group [<xref rid="B134" ref-type="bibr">134</xref>]. This anti-dsDNA virus drug hydrolyzes to CDV after entering into host's cells and is then phosphorylated to CVD-pp to the inhibition of DNA replication. The coadministration of tecovirimat with BCV can reduce the effective concentration (EC<sub>50</sub>) of the latter [<xref rid="B135" ref-type="bibr">135</xref>]. BCV has a long half-life similar to CDV but with reduced nephrotoxicity due to its lipophilicity. Additionally, BCV has significant concentrations in the lungs, spleen, and liver [<xref rid="B136" ref-type="bibr">136</xref>&#8211;<xref rid="B138" ref-type="bibr">138</xref>]. BCV has the potential to raise liver enzyme levels, particularly alanine aminotransferase (ALT), and raise bilirubin levels, which can cause damage to liver cells (hepatocellular toxicity) [<xref rid="B139" ref-type="bibr">139</xref>, <xref rid="B140" ref-type="bibr">140</xref>]. The fasting state reduces BCV's orally absorption and plasma concentration [<xref rid="B141" ref-type="bibr">141</xref>]. BCV is not a recommended drug for pregnant or breastfeeding women. <xref rid="tab2" ref-type="table"> Table 2</xref> compares therapeutic agents for MPOX, including their mechanisms of action, pharmacokinetics, adverse effects, and safety profiles. Tecovirimat is versatile and safe for various populations, while BCV requires hepatic monitoring, and CDV demands renal precautions. This analysis aids clinicians in tailoring treatments based on patient-specific needs and contraindications.</p><p>Immunoglobulin therapy involves the administration of antibodies to enhance the immune response against specific pathogens. The CDC recommends Vaccinia Immune Globulin Intravenous (VIGIV) for the treatment of orthopoxviruses infections, and it has received FDA approval in 2005 for managing complications associated with vaccinia vaccination [<xref rid="B142" ref-type="bibr">142</xref>]. Derived from the plasma of healthy donors, this treatment involves aggregated polyclonal immunoglobulin and has shown cross-neutralization activity against the MPOX virus in a Macaca mulatta model infected with the CB clade of MPOX, effectively inhibiting the virus from infecting additional cells, as depicted in <xref rid="fig2" ref-type="fig">Figure 2</xref> [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B143" ref-type="bibr">143</xref>].</p><p>Imatinib, a drug primarily used for chronic myeloid leukemia, has shown potential as an antiviral agent by disrupting actin dynamics and preventing viral egress. This could reduce the spread of the virus by inhibiting the release of EEVs (see <xref rid="fig3" ref-type="fig">Figure 3</xref>). Other medications have shown effectiveness against MPOX besides imatinib. In a 2017 experiment, resveratrol, found in plants such as grapes, peanuts, and blueberries, hindered virus reproduction by disrupting DNA synthesis [<xref rid="B144" ref-type="bibr">144</xref>]. Ribavirin, a medication commonly used to treat hepatitis C (HCV), has also shown effectiveness against MPOX and other orthopoxviruses infections [<xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B144" ref-type="bibr">144</xref>]. In infected cells treated with recombinant INF-beta (INF-<italic toggle="yes">&#946;</italic>), the antiviral protein myxovirus resistance protein A (MxA) was induced, and it was exhibited that the continuous expression of MxA inhibits MPOX infection [<xref rid="B145" ref-type="bibr">145</xref>]. Further investigations have been carried out to find out the antiviral properties of recombinant beta INF against the MPOX virus.</p><p>For numerous infectious diseases, including MPOX infection, new medication formulations and techniques of administration are in development. A striking example comes from a 2024 study on a poly(lactic-co-glycolic acid) (PLGA) core-enclosed TPE-BT-DPTQ. We further refined the core, combined it, and extruded it under a macrophage membrane. We recovered the membrane by means of mechanical fragmentation, ultracentrifugation, and hypotonic lysis among other techniques. The result of this technique was the final biomimetic nanoparticles (BNPs), sometimes referred to as TBD@M NPs. In this work, photothermal BNPs administered to mice infected with MPOX produced a notable reduction in viral titers within the lesions, accelerated healing of the lesions, and effective inhibition of viral transmission [<xref rid="B146" ref-type="bibr">146</xref>].</p></sec><sec id="sec3.11"><title>3.11. Vaccination</title><p>Because orthopoxviruses share genetic similarities, the immune response to one can help protect against others. Smallpox vaccines can prevent MPOX [<xref rid="B147" ref-type="bibr">147</xref>&#8211;<xref rid="B149" ref-type="bibr">149</xref>]. There are three generations of vaccines against smallpox. The most significant of the first generation of these vaccines, which successfully prevented person-to-person transmission in Africa, is Dryvax&#174; [<xref rid="B150" ref-type="bibr">150</xref>]. The production of Dryvax&#174; was discontinued in the United States in 1978 after 15 million doses had been produced [<xref rid="B151" ref-type="bibr">151</xref>, <xref rid="B152" ref-type="bibr">152</xref>]. Other first-generation vaccines utilizing a live-unattenuated platform, which are no longer licensed, include Lister-based vaccines and the New York City Board of Health (NYCBH) [<xref rid="B152" ref-type="bibr">152</xref>].</p><p>ACAM2000&#174;, a second-generation vaccine developed by Emergent BioSolutions, is a live-attenuated, replication-competent vaccinia virus in lyophilized form. After receiving FDA approval in 2007 [<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B153" ref-type="bibr">153</xref>], this vaccine was introduced as an alternative to Dryvax&#174; and approved for 18&#8211;64-year-old individuals, exhibiting similar safety profiles and complications, including progressive vaccinia, eczema vaccinatum, and encephalitis [<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B154" ref-type="bibr">154</xref>]. ACAM2000&#174;, administered for postexposure prophylaxis with a bifurcated needle, provides peak protection 28&#8201;days after vaccination, with reimmunization advised every three years for high-risk exposures and every 10 years for less virulent strains like cowpox [<xref rid="B155" ref-type="bibr">155</xref>]. Immunosuppressed populations, such as those suffering from leukemia, lymphoma, HIV infection, patients with metastatic malignancies, transplant recipients, and undergoing cancer chemotherapy and radiotherapy individuals or taking corticosteroids with a dose of &#8805; 2&#8201;mg/kg for &#8805; 2&#8201;weeks and TNF inhibitors (e.g., adalimumab and infliximab), are in a group for whom this vaccine is not recommended [<xref rid="B155" ref-type="bibr">155</xref>]. Having cardiac risk factors such as diabetes, smoking, hypertension, or hyperlipidemia is a contraindication for ACAM2000&#174; due to the high risk of myopericarditis, which can present with symptoms such as dyspnea, chest pain, palpitations, and ECG abnormalities in these individuals [<xref rid="B155" ref-type="bibr">155</xref>, <xref rid="B156" ref-type="bibr">156</xref>].</p><p>Unlike ACAM2000&#174;, which is derived from a clonal isolate of Dryvax [<xref rid="B33" ref-type="bibr">33</xref>], LC16m8 is a third-generation vaccine derived from the first-generation Lister strain incorporating a deletion in the B5R immunogenic membrane protein [<xref rid="B157" ref-type="bibr">157</xref>], produced in cell culture using rabbit kidney cells [<xref rid="B158" ref-type="bibr">158</xref>]. This minimally replicating vaccinia virus vaccine has demonstrated effectiveness in postexposure prophylaxis when administered within 4&#8211;14&#8201;days after close contact, regardless of prior smallpox vaccination, and it is the only vaccine authorized for use in children among the three MPOX vaccines [<xref rid="B159" ref-type="bibr">159</xref>].</p><p>Another third-generation vaccine, Modified Vaccinia Ankara (MVA), branded as IMVANEX&#174; (in Canada) and JYNNEOS&#174; (in the United States), has demonstrated adequate cellular and humoral immunity in animal models [<xref rid="B160" ref-type="bibr">160</xref>]. The vaccine is administered intradermally in two doses, specifically on Day 0 and Day 28, by FDA guidelines. This vaccine is exceptionally safe for individuals with compromised immune systems, as it does not use live viruses, significantly reducing the risk of infection [<xref rid="B161" ref-type="bibr">161</xref>].</p><p>In recent years, mRNA-based vaccines have been developed and introduced as novel vaccines, with high efficacy in triggering both humoral and cellular immune responses [<xref rid="B162" ref-type="bibr">162</xref>] and with faster production against tumor cells and viruses [<xref rid="B155" ref-type="bibr">155</xref>]. Self-amplifying RNA (saRNA) [<xref rid="B163" ref-type="bibr">163</xref>] and nonreplicating mRNA vaccines [<xref rid="B164" ref-type="bibr">164</xref>] are two types of RNA vaccines. saRNA vaccines contain the code for both the target antigen and a replicase complex [<xref rid="B165" ref-type="bibr">165</xref>], while nonreplicating vaccines contain the code for only the target antigen [<xref rid="B155" ref-type="bibr">155</xref>]. In addition to viral infections [<xref rid="B166" ref-type="bibr">166</xref>], the applications of saRNA vaccines have expanded to include bacterial infections [<xref rid="B167" ref-type="bibr">167</xref>], parasitic infections [<xref rid="B168" ref-type="bibr">168</xref>], and cancers (through passive vaccination with monoclonal antibodies encoding) [<xref rid="B169" ref-type="bibr">169</xref>, <xref rid="B170" ref-type="bibr">170</xref>]. The MPOX is a new target for this novel vaccine technology. For instance, in Sang and colleagues' study, the immunogenicity of an MPOX virus quadrivalent mRNA vaccine, which was prepared using A29L, A35R, M1R, and B6R as antigen targets, was evaluated in mice. As a result, they observed a strong cellular and memory cell immune response against MPOX without any significant rise in inflammatory cytokines or histopathological changes in the mice [<xref rid="B171" ref-type="bibr">171</xref>]. A multiepitope-based vaccine is another novel approach against MPOX, which Shantier and coworkers have developed. This safe, innovative vaccine elicits an immune response against the MPOX by utilizing cell surface binding proteins, without causing side effects [<xref rid="B172" ref-type="bibr">172</xref>].</p></sec><sec id="sec3.12"><title>3.12. AI and MPOX</title><p>Deep learning (DL) is a specific branch of machine learning (ML) that falls within the broader field of AI. It is distinguished by its capacity to utilize neural networks with numerous layers to identify and represent intricate patterns in large datasets. DL has gained significant recognition for its revolutionary applications in the field of medical science. Significantly, it aids in the identification of illnesses by allowing the examination of various imaging techniques, spanning from basic skin pictures [<xref rid="B173" ref-type="bibr">173</xref>] to advanced diagnostic instruments such as CT scans [<xref rid="B174" ref-type="bibr">174</xref>] and MRIs [<xref rid="B175" ref-type="bibr">175</xref>], largely utilizing convolutional neural networks (CNNs). Furthermore, DL plays a crucial role in the detection of pathogens via genomic sequencing. Utilizing recurrent neural networks (RNNs) improve diagnostic accuracy. Recent research on highly transmissible infectious diseases like MPOX has focused on DL to examine skin lesions and detect them early. In a 2022 study, MobileNetv2 showed the highest accuracy at 91.11% in binary classification with a sample size of 169. VGG16 and VGG19 are CNN models trained on ImageNet, while ResNet50 and ResNet101 are residual networks [<xref rid="B176" ref-type="bibr">176</xref>]. The Vision Transformer (ViT), introduced by Dosovitskiy et al., is a pretrained model for image classification that treats images as sequences of patches processed by a transformer encoder (TE), with a multilayer perceptron (MLP) normalizer, multihead attention mechanism (MHAM), and embedded patches (EPs) forming its architecture [<xref rid="B177" ref-type="bibr">177</xref>]. This new model has uses outside the ones described. In a study by Chaturvedi et al. on the epidemiological and behavioral elements influencing MPOX transmission, it was proposed that, much as with smallpox vaccination, variations in transmission probability&#8212;whether sexual or nonsexual&#8212;had a significant impact on MPOX in their model. Furthermore, in the absence of pre-exposure vaccination, contact tracing's precision and timeliness proved to be quite important in reducing MPOX flow within the model [<xref rid="B178" ref-type="bibr">178</xref>]. Drug discovery and vaccine production through molecular modeling and virtual screening, personalized treatment aimed at achieving the most therapeutic effect with fewer adverse events, and optimal public health policies are just a few examples of how AI can play a role in medical science.</p></sec><sec id="sec3.13"><title>3.13. Policy Implications and Future Research Studies</title><p>Policymakers should focus on vaccination campaigns targeting high-risk groups, including healthcare workers, MSM, and immunocompromised individuals, particularly in regions with Clade 1b cases. Establishing genomic surveillance systems is also essential for monitoring MPOX strain evolution and enabling proactive health responses.</p><p>Despite progress, gaps remain in MPOX research. The long-term efficacy of existing smallpox vaccines against MPOX is still unclear, and AI diagnostic tools need real-world validation. The transmission dynamics among MSM highlight the importance of understanding demographic factors for effective public health interventions. High rates of HIV coinfection in MPOX patients indicate the need for integrated care approaches.</p><p>Future research should prioritize the development of next-generation MPOX-specific vaccines, mainly using mRNA technologies, and expand the use of AI for outbreak surveillance. Addressing transmission's social and behavioral aspects is crucial for reducing stigma and promoting preventive measures. Evaluating current public health policies will provide valuable insights for refining strategies for future outbreaks. By addressing these issues and utilizing innovative tools, global health systems can enhance their preparedness and response to MPOX and other emerging infectious diseases.</p></sec></sec><sec id="sec4"><title>4. Conclusion</title><p>The COVID-19 pandemic and the 2022 MPOX outbreak highlighted the urgent need to handle viruses and their potential to cause widespread epidemics and devastation [<xref rid="B1" ref-type="bibr">1</xref>]. Developing specific treatments and effective vaccinations for viruses such as SARS-CoV-2, MPOX, Zika virus, and Ebola can be challenging due to mutations that alter transmission patterns and clinical properties. This review contributes to this field by providing comprehensive data on various aspects of MPOX infection.</p><p>Modern medications can be developed with a thorough knowledge of viral structures and the protein and nonprotein components engaged in their pathogenesis and life cycle This knowledge enables the design of drugs against them. Many of these structures can be addressed by medications used for different purposes; network pharmacology helps one to find these targets [<xref rid="B179" ref-type="bibr">179</xref>]. Monoclonal antibodies and new chemical therapies can target these structures. Raising public awareness about immunization, preventive measures, and sexual health behaviors is essential, especially for gay individuals and those with multiple sexual partners.</p><p>Combining traditional knowledge of diseases with modern AI technology can help us tackle the challenges of MPOX more effectively. Policymakers, doctors, and researchers must work together to create strategies that improve preparedness, lower the risks of outbreaks, and enhance patient care. The global health community can strengthen its response to MPOX and other emerging infectious diseases by finding and addressing gaps in our current approach [<xref rid="B180" ref-type="bibr">180</xref>].</p></sec></body><back><sec sec-type="data-availability"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><sec><title>Ethics Statement</title><p>This review does not involve original research on human or animal subjects conducted by the authors. However, all studies included in the review were sourced from the peer-reviewed literature, and it is assumed that these studies adhered to ethical standards as outlined by their respective institutions and regulatory bodies. Where applicable, the original authors' adherence to guidelines such as the Declaration of Helsinki, institutional review board (IRB) approvals, or ethical committee approvals for human and animal studies was considered during the selection process.</p><p>To ensure ethical rigor, our inclusion criteria prioritized studies with clear documentation of ethical compliance. Any studies with ambiguous or missing ethical details were excluded to maintain the integrity of the review. By adhering to these standards, this review aligns with the ethical principles of transparency, responsibility, and accountability in scholarly research.</p><p>The authors guarantee that, once their material has been accepted for publication by the journal, they will not submit the same material or portion thereof to another journal.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec><title>Author Contributions</title><p>S.A.: conceptualization, ideation, investigation, writing, and review and editing. M.A.: investigation, data curation, writing, and review and editing. M.A.: investigation, writing, and review and editing. S.S.-M: investigation, writing, and review and editing.</p></sec><sec><title>Funding</title><p>No funding was received for this manuscript.</p></sec><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forni</surname><given-names>D.</given-names></name><name name-style="western"><surname>Molteni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cagliani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sironi</surname><given-names>M.</given-names></name></person-group><article-title>Geographic Structuring and Divergence Time Frame of Monkeypox Virus in the Endemic Region</article-title><source><italic toggle="yes">Journal of Infectious Diseases</italic></source><year>2023</year><volume>227</volume><issue>6</issue><fpage>742</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiac298</pub-id><pub-id pub-id-type="pmid">35831941</pub-id><pub-id pub-id-type="pmcid">PMC10044091</pub-id></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Casas</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Strahan</surname><given-names>A. G.</given-names></name><etal/></person-group><article-title>A Dermatologic Assessment of 101 Mpox (Monkeypox) Cases from 13 Countries during the 2022 Outbreak: Skin Lesion Morphology, Clinical Course, and Scarring</article-title><source><italic toggle="yes">Journal of the American Academy of Dermatology</italic></source><year>2023</year><volume>88</volume><issue>5</issue><fpage>1066</fpage><lpage>1073</lpage><pub-id pub-id-type="pmid">36641010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2022.12.035</pub-id><pub-id pub-id-type="pmcid">PMC9833815</pub-id></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adnyana</surname><given-names>I. M. D. M.</given-names></name><name name-style="western"><surname>Adiwinoto</surname><given-names>R. P.</given-names></name></person-group><article-title>Navigating Skin Complications Post-mpox Vaccination in Immunocompromised Individuals</article-title><source><italic toggle="yes">Journal of Pakistan Association of Dermatologists</italic></source><year>2024</year><volume>34</volume><issue>3</issue><fpage>797</fpage><lpage>799</lpage></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Khalil</surname><given-names>H. E.</given-names></name><name name-style="western"><surname>Elahmady</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Mpox: Risks and Approaches to Prevention</article-title><source><italic toggle="yes">Journal of infection and public health</italic></source><year>2023</year><volume>16</volume><issue>6</issue><fpage>901</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1016/j.jiph.2023.04.001</pub-id><pub-id pub-id-type="pmid">37062165</pub-id><pub-id pub-id-type="pmcid">PMC10074767</pub-id></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velu</surname><given-names>P. D.</given-names></name><name name-style="western"><surname>Sipley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marino</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Evaluation of a Zoonotic Orthopoxvirus PCR Assay for the Detection of Mpox Virus Infection</article-title><source><italic toggle="yes">Journal of Molecular Diagnostics</italic></source><year>2023</year><volume>25</volume><issue>10</issue><fpage>740</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1016/j.jmoldx.2023.06.010</pub-id><pub-id pub-id-type="pmid">37474002</pub-id></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karagoz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tombuloglu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Alsaeed</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Monkeypox (Mpox) Virus: Classification, Origin, Transmission, Genome Organization, Antiviral Drugs, and Molecular Diagnosis</article-title><source><italic toggle="yes">Journal of infection and public health</italic></source><year>2023</year><volume>16</volume><issue>4</issue><fpage>531</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1016/j.jiph.2023.02.003</pub-id><pub-id pub-id-type="pmid">36801633</pub-id><pub-id pub-id-type="pmcid">PMC9908738</pub-id></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mollaamin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shahriari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Monajjemi</surname><given-names>M.</given-names></name></person-group><article-title>Monkeypox Disease Treatment by Tecovirimat Adsorbed onto Single-Walled Carbon Nanotube through Drug Delivery Method</article-title><source><italic toggle="yes">Journal of the Chilean Chemical Society</italic></source><year>2023</year><volume>68</volume><issue>1</issue><fpage>5796</fpage><lpage>5801</lpage><pub-id pub-id-type="doi">10.4067/S0717-97072023000105796</pub-id></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freyn</surname><given-names>A. W.</given-names></name><name name-style="western"><surname>Atyeo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Earl</surname><given-names>P. L.</given-names></name><etal/></person-group><article-title>An Mpox Virus mRNA-Lipid Nanoparticle Vaccine Confers Protection against Lethal Orthopoxviral Challenge</article-title><source><italic toggle="yes">Science Translational Medicine</italic></source><year>2023</year><volume>15</volume><issue>716</issue><fpage>p. eadg3540</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.adg3540</pub-id><pub-id pub-id-type="pmid">37792954</pub-id></element-citation></ref><ref id="B9" content-type="book"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>von Magnus</surname><given-names>P.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>E. K.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>K. B.</given-names></name><name name-style="western"><surname>Birch Andersen</surname><given-names>A.</given-names></name></person-group><source><italic toggle="yes">A Pox-like Disease in Cynomolgus Monkeys</italic></source><year>1959</year><publisher-name>&#8207;</publisher-name></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breman</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Steniowski</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Zanotto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gromyko</surname><given-names>A. I.</given-names></name><name name-style="western"><surname>Arita</surname><given-names>I.</given-names></name></person-group><article-title>Human Monkeypox, 1970-79</article-title><source><italic toggle="yes">Bulletin of the World Health Organization</italic></source><year>1980</year><volume>58</volume><issue>2</issue><fpage>p. 165</fpage><pub-id pub-id-type="doi">10.1099/0022-1317-45-3-683</pub-id><pub-id pub-id-type="other">2-s2.0-0018614984</pub-id><pub-id pub-id-type="pmcid">PMC2395797</pub-id><pub-id pub-id-type="pmid">6249508</pub-id></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sale</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Melski</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Stratman</surname><given-names>E. J.</given-names></name></person-group><article-title>Monkeypox: an Epidemiologic and Clinical Comparison of African and US Disease</article-title><source><italic toggle="yes">Journal of the American Academy of Dermatology</italic></source><year>2006</year><volume>55</volume><issue>3</issue><fpage>478</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2006.05.061</pub-id><pub-id pub-id-type="other">2-s2.0-33746906693</pub-id><pub-id pub-id-type="pmid">16908354</pub-id><pub-id pub-id-type="pmcid">PMC9629018</pub-id></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zahmatyar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fazlollahi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Motamedi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Human Monkeypox: History, Presentations, Transmission, Epidemiology, Diagnosis, Treatment, and Prevention</article-title><source><italic toggle="yes">Frontiers of Medicine</italic></source><year>2023</year><volume>10</volume><fpage>p. 1157670</fpage><pub-id pub-id-type="doi">10.3389/fmed.2023.1157670</pub-id><pub-id pub-id-type="pmcid">PMC10397518</pub-id><pub-id pub-id-type="pmid">37547598</pub-id></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heymann</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Szczeniowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Esteves</surname><given-names>K.</given-names></name></person-group><article-title>Re-emergence of Monkeypox in Africa: a Review of the Past Six Years</article-title><source><italic toggle="yes">British Medical Bulletin</italic></source><year>1998</year><volume>54</volume><issue>3</issue><fpage>693</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.bmb.a011720</pub-id><pub-id pub-id-type="other">2-s2.0-0031751486</pub-id><pub-id pub-id-type="pmid">10326294</pub-id></element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinstein</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Nalca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rimoin</surname><given-names>A. W.</given-names></name><name name-style="western"><surname>Bavari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Whitehouse</surname><given-names>C. A.</given-names></name></person-group><article-title>Reemergence of Monkeypox: Prevalence, Diagnostics, and Countermeasures</article-title><source><italic toggle="yes">Clinical Infectious Diseases</italic></source><year>2005</year><volume>41</volume><issue>12</issue><fpage>1765</fpage><lpage>1771</lpage><pub-id pub-id-type="doi">10.1086/498155</pub-id><pub-id pub-id-type="other">2-s2.0-28744431693</pub-id><pub-id pub-id-type="pmid">16288402</pub-id></element-citation></ref><ref id="B15" content-type="article"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutin</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Malfait</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Outbreak of Human Monkeypox, Democratic Republic of Congo, 1996 to 1997</article-title><source><italic toggle="yes">Emerging Infectious Diseases</italic></source><year>2001</year><volume>7</volume><issue>3</issue><fpage>p. 434</fpage><pub-id pub-id-type="doi">10.3201/eid0703.010311</pub-id><pub-id pub-id-type="pmcid">PMC2631782</pub-id><pub-id pub-id-type="pmid">11384521</pub-id></element-citation></ref><ref id="B16" content-type="article"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Melski</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>M. B.</given-names></name><etal/></person-group><article-title>The Detection of Monkeypox in Humans in the Western Hemisphere</article-title><source><italic toggle="yes">New England Journal of Medicine</italic></source><year>2004</year><volume>350</volume><issue>4</issue><fpage>342</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa032299</pub-id><pub-id pub-id-type="other">2-s2.0-9144245593</pub-id><pub-id pub-id-type="pmid">14736926</pub-id></element-citation></ref><ref id="B17" content-type="article"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durski</surname><given-names>K. N.</given-names></name></person-group><article-title>Emergence of Monkeypox&#8212;West and Central Africa, 1970&#8211;2017</article-title><source><italic toggle="yes">MMWR. Morbidity and mortality weekly report</italic></source><year>2018</year><volume>67</volume><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6710a5</pub-id><pub-id pub-id-type="pmcid">PMC5857192</pub-id><pub-id pub-id-type="pmid">29543790</pub-id></element-citation></ref><ref id="B18" content-type="article"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sklenovsk&#225;</surname><given-names>N.</given-names></name><name name-style="western"><surname>Van Ranst</surname><given-names>M.</given-names></name></person-group><article-title>Emergence of Monkeypox as the Most Important Orthopoxvirus Infection in Humans</article-title><source><italic toggle="yes">Frontiers in Public Health</italic></source><year>2018</year><volume>6</volume><fpage>p. 383729</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2018.00241</pub-id><pub-id pub-id-type="pmcid">PMC6131633</pub-id><pub-id pub-id-type="pmid">30234087</pub-id></element-citation></ref><ref id="B19" content-type="article"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahimi</surname><given-names>F. S.</given-names></name><name name-style="western"><surname>Afaghi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tarki</surname><given-names>F. E.</given-names></name><etal/></person-group><article-title>The Historical Epidemiology of Human Monkeypox: A Review of Evidence from the 1970 Emergence to the 2022 Outbreak</article-title><source><italic toggle="yes">Tohoku Journal of Experimental Medicine</italic></source><year>2022</year><volume>258</volume><issue>4</issue><fpage>243</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1620/tjem.2022.J081</pub-id><pub-id pub-id-type="pmid">36198504</pub-id></element-citation></ref><ref id="B20" content-type="article"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erez</surname><given-names>N.</given-names></name><name name-style="western"><surname>Achdout</surname><given-names>H.</given-names></name><name name-style="western"><surname>Milrot</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Diagnosis of Imported Monkeypox, Israel, 2018</article-title><source><italic toggle="yes">Emerging Infectious Diseases</italic></source><year>2019</year><volume>25</volume><issue>5</issue><fpage>p. 980</fpage><pub-id pub-id-type="doi">10.3201/eid2505.190076</pub-id><pub-id pub-id-type="other">2-s2.0-85065047387</pub-id><pub-id pub-id-type="pmcid">PMC6478227</pub-id><pub-id pub-id-type="pmid">30848724</pub-id></element-citation></ref><ref id="B21" content-type="article"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaughan</surname><given-names>A.</given-names></name></person-group><article-title>Two Cases of Monkeypox Imported</article-title><source><italic toggle="yes">Euro Surveillance</italic></source><year>2018</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2018.23.38.1800509</pub-id><pub-id pub-id-type="pmcid">PMC6157091</pub-id><pub-id pub-id-type="pmid">30255836</pub-id></element-citation></ref><ref id="B22" content-type="article"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adegboye</surname><given-names>O. A.</given-names></name><name name-style="western"><surname>Eugenia Castellanos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alele</surname><given-names>F. O.</given-names></name><etal/></person-group><article-title>Travel-related Monkeypox Outbreaks in the Era of COVID-19 Pandemic: Are We Prepared?</article-title><source><italic toggle="yes">Viruses</italic></source><year>2022</year><volume>14</volume><issue>6</issue><fpage>p. 1283</fpage><pub-id pub-id-type="doi">10.3390/v14061283</pub-id><pub-id pub-id-type="pmcid">PMC9228578</pub-id><pub-id pub-id-type="pmid">35746754</pub-id></element-citation></ref><ref id="B23" content-type="misc"><label>23</label><element-citation publication-type="other"><collab>Organization Who</collab><article-title>WHO Director-General Declares Mpox Outbreak a Public Health Emergency of International Concern 2024</article-title><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern" ext-link-type="uri">https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern</ext-link></comment><pub-id pub-id-type="pmcid">PMC11376700</pub-id><pub-id pub-id-type="pmid">39218470</pub-id></element-citation></ref><ref id="B24" content-type="misc"><label>24</label><element-citation publication-type="other"><article-title>Multi-country Outbreak of Mpox 2024</article-title><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report-35--12-august-2024" ext-link-type="uri">https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report-35--12-august-2024</ext-link></comment></element-citation></ref><ref id="B25" content-type="misc"><label>25</label><element-citation publication-type="other"><article-title>One Case of Mpox Clade I Reported in Sweden</article-title><year>2024</year><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-control/disease-information-about-mpox/one-case-of-mpox-clade-i-reported-in-sweden/" ext-link-type="uri">https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-control/disease-information-about-mpox/one-case-of-mpox-clade-i-reported-in-sweden/</ext-link></comment></element-citation></ref><ref id="B26" content-type="book"><label>26</label><element-citation publication-type="book"><source><italic toggle="yes">Pakistan Says One Case of Mpox Virus Detected</italic></source><publisher-name>European agency raises alert</publisher-name><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.aljazeera.com/news/2024/8/16/pakistan-says-at-least-one-case-of-mpox-virus-detected" ext-link-type="uri">https://www.aljazeera.com/news/2024/8/16/pakistan-says-at-least-one-case-of-mpox-virus-detected</ext-link></comment></element-citation></ref><ref id="B27" content-type="misc"><label>27</label><element-citation publication-type="other"><article-title>Philippines Reports First Mpox Case since W.H.O. Declared Global Emergency</article-title><year>2024</year><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nytimes.com/2024/08/19/world/asia/philippines-mpox-case.html" ext-link-type="uri">https://www.nytimes.com/2024/08/19/world/asia/philippines-mpox-case.html</ext-link></comment></element-citation></ref><ref id="B28" content-type="article"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falendysz</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Lopera</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Doty</surname><given-names>J. B.</given-names></name><etal/></person-group><article-title>Characterization of Monkeypox Virus Infection in African Rope Squirrels (Funisciurus sp.)</article-title><source><italic toggle="yes">PLoS Neglected Tropical Diseases</italic></source><year>2017</year><volume>11</volume><issue>8</issue><fpage>p. e0005809</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0005809</pub-id><pub-id pub-id-type="other">2-s2.0-85028776076</pub-id><pub-id pub-id-type="pmcid">PMC5578676</pub-id><pub-id pub-id-type="pmid">28827792</pub-id></element-citation></ref><ref id="B29" content-type="article"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radoni&#263;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Metzger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dabrowski</surname><given-names>P. W.</given-names></name><etal/></person-group><article-title>Fatal Monkeypox in Wild-Living Sooty Mangabey, C&#244;te d&#8217;Ivoire, 2012</article-title><source><italic toggle="yes">Emerging Infectious Diseases</italic></source><year>2014</year><volume>20</volume><issue>6</issue><fpage>p. 1009</fpage><pub-id pub-id-type="doi">10.3201/eid2006.131329</pub-id><pub-id pub-id-type="other">2-s2.0-84901018828</pub-id><pub-id pub-id-type="pmcid">PMC4036778</pub-id><pub-id pub-id-type="pmid">24857667</pub-id></element-citation></ref><ref id="B30" content-type="article"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liszewski</surname><given-names>M. K.</given-names></name><etal/></person-group><article-title>Virulence Differences between Monkeypox Virus Isolates from West Africa and the Congo Basin</article-title><source><italic toggle="yes">Virology</italic></source><year>2005</year><volume>340</volume><issue>1</issue><fpage>46</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2005.05.030</pub-id><pub-id pub-id-type="other">2-s2.0-23944512221</pub-id><pub-id pub-id-type="pmid">16023693</pub-id><pub-id pub-id-type="pmcid">PMC9534023</pub-id></element-citation></ref><ref id="B31" content-type="article"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Djuicy</surname><given-names>D. D.</given-names></name></person-group><article-title>Concurrent Clade I and Clade II Monkeypox Virus Circulation</article-title><source><italic toggle="yes">Emerging Infectious Diseases</italic></source><year>2024</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid3003.230861</pub-id><pub-id pub-id-type="pmcid">PMC10902553</pub-id><pub-id pub-id-type="pmid">38325363</pub-id></element-citation></ref><ref id="B32" content-type="article"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Likos</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Sammons</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>V. A.</given-names></name><etal/></person-group><article-title>A Tale of Two Clades: Monkeypox Viruses</article-title><source><italic toggle="yes">Journal of General Virology</italic></source><year>2005</year><volume>86</volume><issue>10</issue><fpage>2661</fpage><lpage>2672</lpage><pub-id pub-id-type="doi">10.1099/vir.0.81215-0</pub-id><pub-id pub-id-type="other">2-s2.0-26244436841</pub-id><pub-id pub-id-type="pmid">16186219</pub-id></element-citation></ref><ref id="B33" content-type="article"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitj&#224;</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ogoina</surname><given-names>D.</given-names></name><name name-style="western"><surname>Titanji</surname><given-names>B. K.</given-names></name><etal/></person-group><article-title>Monkeypox</article-title><source><italic toggle="yes">The Lancet</italic></source><year>2023</year><volume>401</volume><issue>10370</issue><fpage>60</fpage><lpage>74</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(22)02075-X</pub-id><pub-id pub-id-type="pmcid">PMC9671644</pub-id><pub-id pub-id-type="pmid">36403582</pub-id></element-citation></ref><ref id="B34" content-type="article"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beer</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>V. B.</given-names></name></person-group><article-title>A Systematic Review of the Epidemiology of Human Monkeypox Outbreaks and Implications for Outbreak Strategy</article-title><source><italic toggle="yes">PLoS Neglected Tropical Diseases</italic></source><year>2019</year><volume>13</volume><issue>10</issue><fpage>p. e0007791</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0007791</pub-id><pub-id pub-id-type="pmcid">PMC6816577</pub-id><pub-id pub-id-type="pmid">31618206</pub-id></element-citation></ref><ref id="B35" content-type="article"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yinka-Ogunleye</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aruna</surname><given-names>O.</given-names></name><name name-style="western"><surname>Dalhat</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Outbreak of Human Monkeypox in Nigeria in 2017&#8211;18: a Clinical and Epidemiological Report</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2019</year><volume>19</volume><issue>8</issue><fpage>872</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30294-4</pub-id><pub-id pub-id-type="other">2-s2.0-85069688973</pub-id><pub-id pub-id-type="pmid">31285143</pub-id><pub-id pub-id-type="pmcid">PMC9628943</pub-id></element-citation></ref><ref id="B36" content-type="article"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giorgi</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Pozzobon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Di Meglio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mercatelli</surname><given-names>D.</given-names></name></person-group><article-title>Genomic Analysis of the Recent Monkeypox Outbreak</article-title><source><italic toggle="yes">bioRxiv</italic></source><year>2022</year><volume>2022-06</volume><pub-id pub-id-type="doi">10.1101/2022.06.01.494368</pub-id></element-citation></ref><ref id="B37" content-type="article"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liszewski</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Hauhart</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Structure and Regulatory Profile of the Monkeypox Inhibitor of Complement: Comparison to Homologs in Vaccinia and variola and Evidence for Dimer Formation</article-title><source><italic toggle="yes">The Journal of Immunology</italic></source><year>2006</year><volume>176</volume><issue>6</issue><fpage>3725</fpage><lpage>3734</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.6.3725</pub-id><pub-id pub-id-type="other">2-s2.0-33644843082</pub-id><pub-id pub-id-type="pmid">16517741</pub-id></element-citation></ref><ref id="B38" content-type="article"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harapan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ophinni</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Megawati</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Monkeypox: a Comprehensive Review</article-title><source><italic toggle="yes">Viruses</italic></source><year>2022</year><volume>14</volume><issue>10</issue><fpage>p. 2155</fpage><pub-id pub-id-type="doi">10.3390/v14102155</pub-id><pub-id pub-id-type="pmcid">PMC9612348</pub-id><pub-id pub-id-type="pmid">36298710</pub-id></element-citation></ref><ref id="B39" content-type="article"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luna</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ram&#237;rez</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Mu&#241;oz</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Phylogenomic Analysis of the Monkeypox Virus (MPXV) 2022 Outbreak: Emergence of a Novel Viral Lineage?</article-title><source><italic toggle="yes">Travel Medicine and Infectious Disease</italic></source><year>2022</year><volume>49</volume><fpage>p. 102402</fpage><pub-id pub-id-type="doi">10.1016/j.tmaid.2022.102402</pub-id><pub-id pub-id-type="pmcid">PMC9628808</pub-id><pub-id pub-id-type="pmid">35840078</pub-id></element-citation></ref><ref id="B40" content-type="article"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Fern&#225;ndez</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Quezada</surname><given-names>D.</given-names></name><name name-style="western"><surname>Casillas-Mu&#241;oz</surname><given-names>F. A. G.</given-names></name><etal/></person-group><article-title>Human Monkeypox: a Comprehensive Overview of Epidemiology, Pathogenesis, Diagnosis, Treatment, and Prevention Strategies</article-title><source><italic toggle="yes">Pathogens</italic></source><year>2023</year><volume>12</volume><issue>7</issue><fpage>p. 947</fpage><pub-id pub-id-type="doi">10.3390/pathogens12070947</pub-id><pub-id pub-id-type="pmcid">PMC10384102</pub-id><pub-id pub-id-type="pmid">37513794</pub-id></element-citation></ref><ref id="B41" content-type="article"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uhteg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mostafa</surname><given-names>H. H.</given-names></name></person-group><article-title>Validation and Implementation of an Orthopoxvirus Qualitative Real-Time PCR for the Diagnosis of Monkeypox in the Clinical Laboratory</article-title><source><italic toggle="yes">Journal of Clinical Virology</italic></source><year>2023</year><volume>158</volume><fpage>p. 105327</fpage><pub-id pub-id-type="doi">10.1016/j.jcv.2022.105327</pub-id><pub-id pub-id-type="pmcid">PMC9650690</pub-id><pub-id pub-id-type="pmid">36410160</pub-id></element-citation></ref><ref id="B42" content-type="article"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>V. A.</given-names></name><name name-style="western"><surname>Laue</surname><given-names>T.</given-names></name><name name-style="western"><surname>Laker</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Damon</surname><given-names>I. K.</given-names></name></person-group><article-title>Detection of Monkeypox Virus with Real-Time PCR Assays</article-title><source><italic toggle="yes">Journal of Clinical Virology</italic></source><year>2006</year><volume>36</volume><issue>3</issue><fpage>194</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2006.03.012</pub-id><pub-id pub-id-type="other">2-s2.0-33745112122</pub-id><pub-id pub-id-type="pmid">16731033</pub-id><pub-id pub-id-type="pmcid">PMC9628957</pub-id></element-citation></ref><ref id="B43" content-type="article"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Oliveira Thomasi</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>da Silva Correa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Silva do Carmo</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Molecular Methods for Diagnosis of Monkeypox: A Mini-Review</article-title><source><italic toggle="yes">Current Molecular Medicine</italic></source><year>2024</year><volume>24</volume><issue>10</issue><fpage>1208</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.2174/1566524023666230717141920</pub-id><pub-id pub-id-type="pmid">37461338</pub-id></element-citation></ref><ref id="B44" content-type="book"><label>44</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>S. C.</given-names></name></person-group><source><italic toggle="yes">Identification of Pan-Orthopoxvirus, Monkeypox-specific and Smallpox-specific DNAs by Real-Time PCR Assay</italic></source><year>2013</year></element-citation></ref><ref id="B45" content-type="article"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wawina-Bokalanga</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sklenovska</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vanmechelen</surname><given-names>B.</given-names></name><etal/></person-group><article-title>An Accurate and Rapid Real-Time PCR Approach for Human Monkeypox Virus Diagnosis</article-title><source><italic toggle="yes">medRxiv</italic></source><year>2022</year></element-citation></ref><ref id="B46" content-type="article"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gelderblom</surname><given-names>H. R.</given-names></name><name name-style="western"><surname>Madeley</surname><given-names>D.</given-names></name></person-group><article-title>Rapid Viral Diagnosis of Orthopoxviruses by Electron Microscopy: Optional or a Must?</article-title><source><italic toggle="yes">Viruses</italic></source><year>2018</year><volume>10</volume><issue>4</issue><fpage>p. 142</fpage><pub-id pub-id-type="doi">10.3390/v10040142</pub-id><pub-id pub-id-type="other">2-s2.0-85044614041</pub-id><pub-id pub-id-type="pmcid">PMC5923436</pub-id><pub-id pub-id-type="pmid">29565285</pub-id></element-citation></ref><ref id="B47" content-type="article"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidle</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wieland</surname><given-names>U.</given-names></name><name name-style="western"><surname>B&#246;er-Auer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Metze</surname><given-names>D.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>S. A.</given-names></name></person-group><article-title>Lives of Skin Lesions in Monkeypox: Histomorphological, Immunohistochemical, and Clinical Correlations in a Small Case Series</article-title><source><italic toggle="yes">Viruses</italic></source><year>2023</year><volume>15</volume><issue>8</issue><fpage>p. 1748</fpage><pub-id pub-id-type="doi">10.3390/v15081748</pub-id><pub-id pub-id-type="pmcid">PMC10458687</pub-id><pub-id pub-id-type="pmid">37632089</pub-id></element-citation></ref><ref id="B48" content-type="article"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Branda</surname><given-names>F.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ciccozzi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Mpox: An Overview of Pathogenesis, Diagnosis, and Public Health Implications</article-title><source><italic toggle="yes">Journal of Clinical Medicine</italic></source><year>2024</year><volume>13</volume><issue>8</issue><fpage>p. 2234</fpage><pub-id pub-id-type="doi">10.3390/jcm13082234</pub-id><pub-id pub-id-type="pmcid">PMC11050819</pub-id><pub-id pub-id-type="pmid">38673507</pub-id></element-citation></ref><ref id="B49" content-type="article"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Hammarlund</surname><given-names>E.</given-names></name><name name-style="western"><surname>Slifka</surname><given-names>M. K.</given-names></name></person-group><article-title>Optimization of Peptide-Based ELISA for Serological Diagnostics: a Retrospective Study of Human Monkeypox Infection</article-title><source><italic toggle="yes">Vector Borne and Zoonotic Diseases</italic></source><year>2012</year><volume>12</volume><issue>5</issue><fpage>400</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1089/vbz.2011.0779</pub-id><pub-id pub-id-type="other">2-s2.0-84861060214</pub-id><pub-id pub-id-type="pmid">22217169</pub-id><pub-id pub-id-type="pmcid">PMC3353756</pub-id></element-citation></ref><ref id="B50" content-type="article"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minhaj</surname><given-names>F. S.</given-names></name><name name-style="western"><surname>Ogale</surname><given-names>Y. P.</given-names></name><name name-style="western"><surname>Whitehill</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Monkeypox Outbreak&#8212;Nine States</article-title><source><italic toggle="yes">&#8207;</italic></source><year>2022</year><issue>23</issue><fpage>764</fpage><lpage>769</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7123e1</pub-id><pub-id pub-id-type="pmcid">PMC9181052</pub-id><pub-id pub-id-type="pmid">35679181</pub-id></element-citation></ref><ref id="B51" content-type="article"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guzzetta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mammone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferraro</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Early Estimates of Monkeypox Incubation Period, Generation Time, and Reproduction Number, Italy, May&#8211;June 2022</article-title><source><italic toggle="yes">Emerging Infectious Diseases</italic></source><year>2022</year><volume>28</volume><issue>10</issue><fpage>p. 2078</fpage><pub-id pub-id-type="doi">10.3201/eid2810.221126</pub-id><pub-id pub-id-type="pmcid">PMC9514338</pub-id><pub-id pub-id-type="pmid">35994726</pub-id></element-citation></ref><ref id="B52" content-type="book"><label>52</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Charniga</surname><given-names>K.</given-names></name><name name-style="western"><surname>Masters</surname><given-names>N. B.</given-names></name><name name-style="western"><surname>Slayton</surname><given-names>R. B.</given-names></name><etal/></person-group><source><italic toggle="yes">Estimating the Incubation Period of Monkeypox Virus during the 2022 Multi-National Outbreak</italic></source><year>2022</year><publisher-name>&#8207;</publisher-name></element-citation></ref><ref id="B53" content-type="article"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huhn</surname><given-names>G. D.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Yorita</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Clinical Characteristics of Human Monkeypox, and Risk Factors for Severe Disease</article-title><source><italic toggle="yes">Clinical Infectious Diseases</italic></source><year>2005</year><volume>41</volume><issue>12</issue><fpage>1742</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.1086/498115</pub-id><pub-id pub-id-type="other">2-s2.0-28744456362</pub-id><pub-id pub-id-type="pmid">16288398</pub-id></element-citation></ref><ref id="B54" content-type="book"><label>54</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Miura</surname><given-names>F.</given-names></name><name name-style="western"><surname>van Ewijk</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Backer</surname><given-names>J. A.</given-names></name><etal/></person-group><source><italic toggle="yes">Estimated Incubation Period for Monkeypox Cases Confirmed in the Netherlands</italic></source><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2022.27.24.2200448</pub-id><pub-id pub-id-type="pmcid">PMC9205160</pub-id><pub-id pub-id-type="pmid">35713026</pub-id></element-citation></ref><ref id="B55" content-type="article"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacLeod</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Nakatsuji</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Di Nardo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>R. L.</given-names></name></person-group><article-title>Vaccinia Virus Binds to the Scavenger Receptor MARCO on the Surface of Keratinocytes</article-title><source><italic toggle="yes">Journal of Investigative Dermatology</italic></source><year>2015</year><volume>135</volume><issue>1</issue><fpage>142</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/jid.2014.330</pub-id><pub-id pub-id-type="other">2-s2.0-84925956317</pub-id><pub-id pub-id-type="pmid">25089661</pub-id><pub-id pub-id-type="pmcid">PMC4268046</pub-id></element-citation></ref><ref id="B56" content-type="article"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fuhlbrigge</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Pena-Cruz</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lieberman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kupper</surname><given-names>T. S.</given-names></name></person-group><article-title>Vaccinia Virus Induces Strong Immunoregulatory Cytokine Production in Healthy Human Epidermal Keratinocytes: a Novel Strategy for Immune Evasion</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2005</year><volume>79</volume><issue>12</issue><fpage>7363</fpage><lpage>7370</lpage><pub-id pub-id-type="doi">10.1128/jvi.79.12.7363-7370.2005</pub-id><pub-id pub-id-type="other">2-s2.0-19944412730</pub-id><pub-id pub-id-type="pmid">15919891</pub-id><pub-id pub-id-type="pmcid">PMC1143660</pub-id></element-citation></ref><ref id="B57" content-type="article"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahsan</surname><given-names>O.</given-names></name><name name-style="western"><surname>Muhammad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Waheed</surname><given-names>Y.</given-names></name></person-group><article-title>Monkeypox Virus: a Comprehensive Overview of Viral Pathology, Immune Response, and Antiviral Strategies</article-title><source><italic toggle="yes">Vaccines</italic></source><year>2023</year><volume>11</volume><issue>8</issue><fpage>p. 1345</fpage><pub-id pub-id-type="doi">10.3390/vaccines11081345</pub-id><pub-id pub-id-type="pmcid">PMC10459537</pub-id><pub-id pub-id-type="pmid">37631913</pub-id></element-citation></ref><ref id="B58" content-type="article"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaucha</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Jahrling</surname><given-names>P. B.</given-names></name><name name-style="western"><surname>Geisbert</surname><given-names>T. W.</given-names></name><name name-style="western"><surname>Swearengen</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>L.</given-names></name></person-group><article-title>The Pathology of Experimental Aerosolized Monkeypox Virus Infection in Cynomolgus Monkeys (Macaca fascicularis)</article-title><source><italic toggle="yes">Laboratory Investigation</italic></source><year>2001</year><volume>81</volume><issue>12</issue><fpage>1581</fpage><lpage>1600</lpage><pub-id pub-id-type="doi">10.1038/labinvest.3780373</pub-id><pub-id pub-id-type="other">2-s2.0-0035206041</pub-id><pub-id pub-id-type="pmid">11742030</pub-id><pub-id pub-id-type="pmcid">PMC9827346</pub-id></element-citation></ref><ref id="B59" content-type="article"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tree</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Sequence of Pathogenic Events in Cynomolgus Macaques Infected with Aerosolized Monkeypox Virus</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2015</year><volume>89</volume><issue>8</issue><fpage>4335</fpage><lpage>4344</lpage><pub-id pub-id-type="doi">10.1128/jvi.03029-14</pub-id><pub-id pub-id-type="other">2-s2.0-84925424658</pub-id><pub-id pub-id-type="pmid">25653439</pub-id><pub-id pub-id-type="pmcid">PMC4442344</pub-id></element-citation></ref><ref id="B60" content-type="article"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saijo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ami</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suzaki</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Virulence and Pathophysiology of the Congo Basin and West African Strains of Monkeypox Virus in Non-human Primates</article-title><source><italic toggle="yes">Journal of General Virology</italic></source><year>2009</year><volume>90</volume><issue>9</issue><fpage>2266</fpage><lpage>2271</lpage><pub-id pub-id-type="doi">10.1099/vir.0.010207-0</pub-id><pub-id pub-id-type="other">2-s2.0-70349333848</pub-id><pub-id pub-id-type="pmid">19474247</pub-id></element-citation></ref><ref id="B61" content-type="article"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anwar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Haider</surname><given-names>F.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Clinical Manifestation, Transmission, Pathogenesis, and Diagnosis of Monkeypox Virus: a Comprehensive Review</article-title><source><italic toggle="yes">Life</italic></source><year>2023</year><volume>13</volume><issue>2</issue><fpage>p. 522</fpage><pub-id pub-id-type="doi">10.3390/life13020522</pub-id><pub-id pub-id-type="pmid">36836879</pub-id><pub-id pub-id-type="pmcid">PMC9962527</pub-id></element-citation></ref><ref id="B62" content-type="book"><label>62</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>S. C.</given-names></name></person-group><source><italic toggle="yes">Discovery of Antivirals against Smallpox</italic></source><year>2004</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0403600101</pub-id><pub-id pub-id-type="pmcid">PMC509180</pub-id><pub-id pub-id-type="pmid">15249657</pub-id></element-citation></ref><ref id="B63" content-type="article"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zandi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shafaati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>F.</given-names></name></person-group><article-title>Mechanisms of Immune Evasion of Monkeypox Virus</article-title><source><italic toggle="yes">Frontiers in Microbiology</italic></source><year>2023</year><volume>14</volume><fpage>p. 1106247</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2023.1106247</pub-id><pub-id pub-id-type="pmcid">PMC9928851</pub-id><pub-id pub-id-type="pmid">36819041</pub-id></element-citation></ref><ref id="B64" content-type="article"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsalik</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Fiorino</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aqeel</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The Host Response to Viral Infections Reveals Common and Virus-specific Signatures in the Peripheral Blood</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2021</year><volume>12</volume><fpage>p. 741837</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.741837</pub-id><pub-id pub-id-type="pmid">34777354</pub-id><pub-id pub-id-type="pmcid">PMC8578928</pub-id></element-citation></ref><ref id="B65" content-type="article"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akram</surname><given-names>A.</given-names></name><name name-style="western"><surname>Inman</surname><given-names>R. D.</given-names></name></person-group><article-title>Immunodominance: a Pivotal Principle in Host Response to Viral Infections</article-title><source><italic toggle="yes">Clinical Immunology</italic></source><year>2012</year><volume>143</volume><issue>2</issue><fpage>99</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2012.01.015</pub-id><pub-id pub-id-type="other">2-s2.0-84859763565</pub-id><pub-id pub-id-type="pmid">22391152</pub-id></element-citation></ref><ref id="B66" content-type="article"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brutkiewicz</surname><given-names>R. R.</given-names></name></person-group><article-title>Cell Signaling Pathways that Regulate Antigen Presentation</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2016</year><volume>197</volume><issue>8</issue><fpage>2971</fpage><lpage>2979</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1600460</pub-id><pub-id pub-id-type="other">2-s2.0-84991449435</pub-id><pub-id pub-id-type="pmcid">PMC5119928</pub-id><pub-id pub-id-type="pmid">27824592</pub-id></element-citation></ref><ref id="B67" content-type="article"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Kaminski</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Kurt-Jones</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K. A.</given-names></name></person-group><article-title>Pattern Recognition Receptors and the Innate Immune Response to Viral Infection</article-title><source><italic toggle="yes">Viruses</italic></source><year>2011</year><volume>3</volume><issue>6</issue><fpage>920</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.3390/v3060920</pub-id><pub-id pub-id-type="other">2-s2.0-79959634861</pub-id><pub-id pub-id-type="pmid">21994762</pub-id><pub-id pub-id-type="pmcid">PMC3186011</pub-id></element-citation></ref><ref id="B68" content-type="article"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shchelkunov</surname><given-names>S. N.</given-names></name></person-group><article-title>Orthopoxvirus Genes that Mediate Disease Virulence and Host Tropism</article-title><source><italic toggle="yes">Advances in Virology</italic></source><year>2012</year><volume>2012</volume><issue>1</issue><fpage>p. 524743</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2012/524743</pub-id><pub-id pub-id-type="pmcid">PMC3413996</pub-id><pub-id pub-id-type="pmid">22899927</pub-id></element-citation></ref><ref id="B69" content-type="article"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z. W.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The IKK<italic toggle="yes">&#946;</italic> Subunit of I<italic toggle="yes">&#954;</italic>B Kinase (IKK) Is Essential for Nuclear Factor <italic toggle="yes">&#954;</italic>B Activation and Prevention of Apoptosis</article-title><source><italic toggle="yes">Journal of Experimental Medicine</italic></source><year>1999</year><volume>189</volume><issue>11</issue><fpage>1839</fpage><lpage>1845</lpage><pub-id pub-id-type="doi">10.1084/jem.189.11.1839</pub-id><pub-id pub-id-type="other">2-s2.0-0033532386</pub-id><pub-id pub-id-type="pmid">10359587</pub-id><pub-id pub-id-type="pmcid">PMC2193082</pub-id></element-citation></ref><ref id="B70" content-type="article"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Youle</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Strasser</surname><given-names>A.</given-names></name></person-group><article-title>The BCL-2 Protein Family: Opposing Activities that Mediate Cell Death</article-title><source><italic toggle="yes">Nature Reviews Molecular Cell Biology</italic></source><year>2008</year><volume>9</volume><issue>1</issue><fpage>47</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1038/nrm2308</pub-id><pub-id pub-id-type="other">2-s2.0-37549048249</pub-id><pub-id pub-id-type="pmid">18097445</pub-id></element-citation></ref><ref id="B71" content-type="article"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>K.</given-names></name><name name-style="western"><surname>Leggat</surname><given-names>P. A.</given-names></name></person-group><article-title>Human Monkeypox: Current State of Knowledge and Implications for the Future</article-title><source><italic toggle="yes">Tropical medicine and infectious disease</italic></source><year>2016</year><volume>1</volume><issue>1</issue><fpage>p. 8</fpage><pub-id pub-id-type="doi">10.3390/tropicalmed1010008</pub-id><pub-id pub-id-type="other">2-s2.0-85056071242</pub-id><pub-id pub-id-type="pmcid">PMC6082047</pub-id><pub-id pub-id-type="pmid">30270859</pub-id></element-citation></ref><ref id="B72" content-type="article"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Buller</surname><given-names>R. M.</given-names></name></person-group><article-title>A Review of Experimental and Natural Infections of Animals with Monkeypox Virus between 1958 and 2012</article-title><source><italic toggle="yes">Future Virology</italic></source><year>2013</year><volume>8</volume><issue>2</issue><fpage>129</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.2217/fvl.12.130</pub-id><pub-id pub-id-type="other">2-s2.0-84873884787</pub-id><pub-id pub-id-type="pmid">23626656</pub-id><pub-id pub-id-type="pmcid">PMC3635111</pub-id></element-citation></ref><ref id="B73" content-type="article"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bunge</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Hoet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><etal/></person-group><article-title>The Changing Epidemiology of Human Monkeypox&#8212;A Potential Threat? A Systematic Review</article-title><source><italic toggle="yes">PLoS Neglected Tropical Diseases</italic></source><year>2022</year><volume>16</volume><issue>2</issue><fpage>p. e0010141</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0010141</pub-id><pub-id pub-id-type="pmcid">PMC8870502</pub-id><pub-id pub-id-type="pmid">35148313</pub-id></element-citation></ref><ref id="B74" content-type="book"><label>74</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>M. G.</given-names></name></person-group><source><italic toggle="yes">Spectrum of Infection and Risk Factors for Human Monkeypox</italic></source><year>2007</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1309.070175</pub-id><pub-id pub-id-type="pmcid">PMC2857287</pub-id><pub-id pub-id-type="pmid">18252104</pub-id></element-citation></ref><ref id="B75" content-type="article"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleischauer</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Kile</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Evaluation of Human-To-Human Transmission of Monkeypox from Infected Patients to Health Care Workers</article-title><source><italic toggle="yes">Clinical Infectious Diseases</italic></source><year>2005</year><volume>40</volume><issue>5</issue><fpage>689</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.3201/eid1309.070175</pub-id><pub-id pub-id-type="other">2-s2.0-34848912220</pub-id><pub-id pub-id-type="pmid">15714414</pub-id></element-citation></ref><ref id="B76" content-type="article"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Sousa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Patroc&#237;nio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frade</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Monkeypox Diagnosis by Cutaneous and Mucosal Findings</article-title><source><italic toggle="yes">Infectious Disease Reports</italic></source><year>2022</year><volume>14</volume><issue>5</issue><fpage>759</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.3390/idr14050077</pub-id><pub-id pub-id-type="pmid">36286198</pub-id><pub-id pub-id-type="pmcid">PMC9602055</pub-id></element-citation></ref><ref id="B77" content-type="article"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mailhe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beaumont</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Thy</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Clinical Characteristics of Ambulatory and Hospitalized Patients with Monkeypox Virus Infection: an Observational Cohort Study</article-title><source><italic toggle="yes">Clinical Microbiology and Infection</italic></source><year>2023</year><volume>29</volume><issue>2</issue><fpage>233</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2022.08.012</pub-id><pub-id pub-id-type="pmid">36028090</pub-id><pub-id pub-id-type="pmcid">PMC9533921</pub-id></element-citation></ref><ref id="B78" content-type="article"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheema</surname><given-names>A. Y.</given-names></name><name name-style="western"><surname>Ogedegbe</surname><given-names>O. J.</given-names></name><name name-style="western"><surname>Munir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alugba</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ojo</surname><given-names>T. K.</given-names></name></person-group><article-title>Monkeypox: a Review of Clinical Features, Diagnosis, and Treatment</article-title><source><italic toggle="yes">Cureus</italic></source><year>2022</year><volume>14</volume><issue>7</issue><pub-id pub-id-type="doi">10.7759/cureus.26756</pub-id><pub-id pub-id-type="pmcid">PMC9365327</pub-id><pub-id pub-id-type="pmid">35967174</pub-id></element-citation></ref><ref id="B79" content-type="article"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benites-Zapata</surname><given-names>V. A.</given-names></name><name name-style="western"><surname>Ulloque-Badaracco</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Alarcon-Braga</surname><given-names>E. A.</given-names></name><etal/></person-group><article-title>Clinical Features, Hospitalisation and Deaths Associated with Monkeypox: a Systematic Review and Meta-Analysis</article-title><source><italic toggle="yes">Annals of Clinical Microbiology and Antimicrobials</italic></source><year>2022</year><volume>21</volume><issue>1</issue><fpage>p. 36</fpage><pub-id pub-id-type="doi">10.1186/s12941-022-00527-1</pub-id><pub-id pub-id-type="pmcid">PMC9364300</pub-id><pub-id pub-id-type="pmid">35948973</pub-id></element-citation></ref><ref id="B80" content-type="article"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fenner</surname><given-names>F.</given-names></name></person-group><article-title>Smallpox: Emergence, Global Spread, and Eradication</article-title><source><italic toggle="yes">History &amp; Philosophy of the Life Sciences</italic></source><year>1993</year><volume>15</volume><issue>3</issue><fpage>397</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">7529932</pub-id></element-citation></ref><ref id="B81" content-type="article"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Giulio</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Eckburg</surname><given-names>P. B.</given-names></name></person-group><article-title>Human Monkeypox: an Emerging Zoonosis</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2004</year><volume>4</volume><issue>1</issue><fpage>15</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(03)00856-9</pub-id><pub-id pub-id-type="other">2-s2.0-0347987052</pub-id><pub-id pub-id-type="pmid">14720564</pub-id><pub-id pub-id-type="pmcid">PMC9628772</pub-id></element-citation></ref><ref id="B82" content-type="book"><label>82</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lima</surname><given-names>E. L. D.</given-names></name><name name-style="western"><surname>Barra</surname><given-names>L. A. C.</given-names></name><name name-style="western"><surname>Borges</surname><given-names>L. M. S.</given-names></name><etal/></person-group><source><italic toggle="yes">First case report of monkeypox in Brazil: clinical manifestations and differential diagnosis with sexually transmitted infections</italic></source><year>2022</year><volume>64</volume><publisher-name>Revista do Instituto de Medicina Tropical de S&#227;o Paulo</publisher-name><fpage>p. e54</fpage><pub-id pub-id-type="doi">10.1590/S1678-9946202264054</pub-id><pub-id pub-id-type="pmcid">PMC9448252</pub-id><pub-id pub-id-type="pmid">36074449</pub-id></element-citation></ref><ref id="B83" content-type="article"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCollum</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Damon</surname><given-names>I. K.</given-names></name></person-group><article-title>Human Monkeypox</article-title><source><italic toggle="yes">Clinical Infectious Diseases</italic></source><year>2014</year><volume>58</volume><issue>2</issue><fpage>260</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1093/cid/cit703</pub-id><pub-id pub-id-type="other">2-s2.0-84891787107</pub-id><pub-id pub-id-type="pmid">24158414</pub-id><pub-id pub-id-type="pmcid">PMC5895105</pub-id></element-citation></ref><ref id="B84" content-type="article"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kantele</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koopmans</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention</article-title><source><italic toggle="yes">Infectious Disease Clinics</italic></source><year>2019</year><volume>33</volume><issue>4</issue><fpage>1027</fpage><lpage>1043</lpage><pub-id pub-id-type="pmid">30981594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.idc.2019.03.001</pub-id><pub-id pub-id-type="pmcid">PMC9533922</pub-id></element-citation></ref><ref id="B85" content-type="book"><label>85</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Abu-Azzam</surname><given-names>O.</given-names></name><name name-style="western"><surname>Abu-Jeyyab</surname><given-names>M.</given-names></name><name name-style="western"><surname>Daradkeh</surname><given-names>M.</given-names></name><etal/></person-group><source><italic toggle="yes">Monkeypox Infection and Pregnancy in Lower and Middle-Income Countries: Precautions &amp; Recommendations</italic></source><year>2024</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.61622/rbgo/2024rbgo54</pub-id><pub-id pub-id-type="pmcid">PMC11239211</pub-id><pub-id pub-id-type="pmid">38994460</pub-id></element-citation></ref><ref id="B86" content-type="article"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guarner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Del Rio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Malani</surname><given-names>P. N.</given-names></name></person-group><article-title>Monkeypox in 2022&#8212;what Clinicians Need to Know</article-title><source><italic toggle="yes">JAMA</italic></source><year>2022</year><volume>328</volume><issue>2</issue><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.10802</pub-id><pub-id pub-id-type="pmid">35696257</pub-id></element-citation></ref><ref id="B87" content-type="article"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cu&#233;rel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Favre</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vouga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pomar</surname><given-names>L.</given-names></name></person-group><article-title>Monkeypox and Pregnancy: Latest Updates</article-title><source><italic toggle="yes">Viruses</italic></source><year>2022</year><volume>14</volume><issue>11</issue><fpage>p. 2520</fpage><pub-id pub-id-type="doi">10.3390/v14112520</pub-id><pub-id pub-id-type="pmcid">PMC9693336</pub-id><pub-id pub-id-type="pmid">36423129</pub-id></element-citation></ref><ref id="B88" content-type="article"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Soni</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A Systematic Review on Human Monkeypox Virus Disease and Infection in Pregnancy</article-title><source><italic toggle="yes">Journal of Pure and Applied Microbiology</italic></source><year>2023</year><volume>17</volume><issue>2</issue><pub-id pub-id-type="doi">10.22207/JPAM.17.2.52</pub-id></element-citation></ref><ref id="B89" content-type="misc"><label>89</label><element-citation publication-type="other"><article-title>Multi-country Monkeypox Outbreak: Situation Update World Health Organization 17 June 2022</article-title><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON393" ext-link-type="uri">https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON393</ext-link></comment></element-citation></ref><ref id="B90" content-type="article"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tar&#237;n-Vicente</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Alemany</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agud-Dios</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Clinical Presentation and Virological Assessment of Confirmed Human Monkeypox Virus Cases in Spain: a Prospective Observational Cohort Study</article-title><source><italic toggle="yes">The Lancet</italic></source><year>2022</year><volume>400</volume><issue>10353</issue><fpage>661</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)01436-2</pub-id><pub-id pub-id-type="pmcid">PMC9533900</pub-id><pub-id pub-id-type="pmid">35952705</pub-id></element-citation></ref><ref id="B91" content-type="article"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angelo</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>T.</given-names></name><name name-style="western"><surname>Camprub&#237;-Ferrer</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Epidemiological and Clinical Characteristics of Patients with Monkeypox in the GeoSentinel Network: a Cross-Sectional Study</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2023</year><volume>23</volume><issue>2</issue><fpage>196</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00651-X</pub-id><pub-id pub-id-type="pmid">36216018</pub-id><pub-id pub-id-type="pmcid">PMC9546520</pub-id></element-citation></ref><ref id="B92" content-type="article"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Catal&#224;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Clavo&#8208;Escribano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Riera&#8208;Monroig</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Monkeypox Outbreak in Spain: Clinical and Epidemiological Findings in a Prospective Cross&#8208;sectional Study of 185 Cases</article-title><source><italic toggle="yes">British Journal of Dermatology</italic></source><year>2022</year><volume>187</volume><issue>5</issue><fpage>765</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">35917191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjd.21790</pub-id></element-citation></ref><ref id="B93" content-type="article"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez-Garberi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sarrio-Sanz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Martinez-Cayuelas</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Genitourinary Lesions Due to Monkeypox</article-title><source><italic toggle="yes">European Urology</italic></source><year>2022</year><volume>82</volume><issue>6</issue><fpage>625</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2022.08.034</pub-id><pub-id pub-id-type="pmid">36096858</pub-id><pub-id pub-id-type="pmcid">PMC9628708</pub-id></element-citation></ref><ref id="B94" content-type="article"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Girometti</surname><given-names>N.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bracchi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Demographic and Clinical Characteristics of Confirmed Human Monkeypox Virus Cases in Individuals Attending a Sexual Health Centre in London, UK: an Observational Analysis</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2022</year><volume>22</volume><issue>9</issue><fpage>1321</fpage><lpage>1328</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00411-X</pub-id><pub-id pub-id-type="pmid">35785793</pub-id><pub-id pub-id-type="pmcid">PMC9534773</pub-id></element-citation></ref><ref id="B95" content-type="article"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>L. B.</given-names></name><name name-style="western"><surname>Bergeron</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cadieux</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Monkeypox in Montr&#233;al: Epidemiology, Phylogenomics, and Public Health Response to a Large North American Outbreak</article-title><source><italic toggle="yes">Annals of Internal Medicine</italic></source><year>2023</year><volume>176</volume><issue>1</issue><fpage>67</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.7326/M22-2699</pub-id><pub-id pub-id-type="pmid">36508736</pub-id></element-citation></ref><ref id="B96" content-type="article"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hennessee</surname><given-names>I.</given-names></name></person-group><article-title>Epidemiologic and Clinical Features of Children and Adolescents Aged 18 Years with Monkeypox&#8212;United States, May 17&#8211;September 24, 2022</article-title><source><italic toggle="yes">MMWR. Morbidity and mortality weekly Report</italic></source><year>2022</year><volume>71</volume><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7144a4</pub-id><pub-id pub-id-type="pmcid">PMC9639439</pub-id><pub-id pub-id-type="pmid">36331124</pub-id></element-citation></ref><ref id="B97" content-type="article"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hornuss</surname><given-names>D.</given-names></name><name name-style="western"><surname>Daehne</surname><given-names>T.</given-names></name><name name-style="western"><surname>Goetz</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Transmission Characteristics, Replication Patterns and Clinical Manifestations of Human Monkeypox Virus&#8212;An In-Depth Analysis of Four Cases from Germany</article-title><source><italic toggle="yes">Clinical Microbiology and Infection</italic></source><year>2023</year><volume>29</volume><issue>1</issue><fpage>p. 112-e5</fpage><pub-id pub-id-type="doi">10.1016/j.cmi.2022.09.012</pub-id><pub-id pub-id-type="pmcid">PMC9534158</pub-id><pub-id pub-id-type="pmid">36155255</pub-id></element-citation></ref><ref id="B98" content-type="article"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez</surname><given-names>J. I.</given-names></name><name name-style="western"><surname>Montalb&#225;n</surname><given-names>E. G.</given-names></name><name name-style="western"><surname>Bueno</surname><given-names>S. J.</given-names></name><etal/></person-group><article-title>Monkeypox Outbreak Predominantly Affecting Men Who Have Sex with Men, Madrid, Spain, 26 April to 16 June 2022</article-title><source><italic toggle="yes">Euro Surveillance</italic></source><year>2022</year><volume>27</volume><issue>27</issue><fpage>p. 2200471</fpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2022.27.27.2200471</pub-id><pub-id pub-id-type="pmcid">PMC9264731</pub-id><pub-id pub-id-type="pmid">35801519</pub-id></element-citation></ref><ref id="B99" content-type="article"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moschese</surname><given-names>D.</given-names></name><name name-style="western"><surname>Giacomelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beltrami</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Hospitalisation for Monkeypox in Milan, Italy</article-title><source><italic toggle="yes">Travel Medicine and Infectious Disease</italic></source><year>2022</year><volume>49</volume><fpage>p. 102417</fpage><pub-id pub-id-type="doi">10.1016/j.tmaid.2022.102417</pub-id><pub-id pub-id-type="pmcid">PMC9760088</pub-id><pub-id pub-id-type="pmid">35934310</pub-id></element-citation></ref><ref id="B100" content-type="article"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>N&#246;rz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brehm</surname><given-names>T. T.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H. T.</given-names></name><etal/></person-group><article-title>Clinical Characteristics and Comparison of Longitudinal qPCR Results from Different Specimen Types in a Cohort of Ambulatory and Hospitalized Patients Infected with Monkeypox Virus</article-title><source><italic toggle="yes">Journal of Clinical Virology</italic></source><year>2022</year><volume>155</volume><fpage>p. 105254</fpage><pub-id pub-id-type="doi">10.1016/j.jcv.2022.105254</pub-id><pub-id pub-id-type="pmcid">PMC9528238</pub-id><pub-id pub-id-type="pmid">36057206</pub-id></element-citation></ref><ref id="B101" content-type="book"><label>101</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bilinska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>J. C.</given-names></name><etal/></person-group><source><italic toggle="yes">Clinical Features and Novel Presentations of Human Monkeypox in a central London centre during the 2022 Outbreak: Descriptive Case Series</italic></source><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj-2022-072410</pub-id><pub-id pub-id-type="pmcid">PMC9331915</pub-id><pub-id pub-id-type="pmid">35902115</pub-id></element-citation></ref><ref id="B102" content-type="book"><label>102</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Philpott</surname><given-names>D.</given-names></name></person-group><source><italic toggle="yes">Epidemiologic and Clinical Characteristics of Monkeypox Cases&#8212;United States</italic></source><year>2022</year><publisher-name>&#8207;</publisher-name><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7132e3</pub-id><pub-id pub-id-type="pmcid">PMC9400536</pub-id><pub-id pub-id-type="pmid">35951487</pub-id></element-citation></ref><ref id="B103" content-type="article"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thornhill</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Barkati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Walmsley</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Monkeypox virus infection in humans across 16 countries&#8212;April&#8211;June 2022</article-title><source><italic toggle="yes">New England Journal of Medicine</italic></source><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2207323</pub-id><pub-id pub-id-type="pmid">35866746</pub-id></element-citation></ref><ref id="B104" content-type="article"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jessen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wyen</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Clinical Characteristics of Monkeypox Virus Infections Among Men with and without HIV: a Large Outbreak Cohort in Germany</article-title><source><italic toggle="yes">HIV Medicine</italic></source><year>2023</year><volume>24</volume><issue>4</issue><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">36059149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/hiv.13378</pub-id></element-citation></ref><ref id="B105" content-type="article"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Ewijk</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Miura</surname><given-names>F.</given-names></name><name name-style="western"><surname>van Rijckevorsel</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Mpox Outbreak in the Netherlands, 2022: Public Health Response, Characteristics of the First 1,000 Cases and Protection of the First-Generation Smallpox Vaccine</article-title><source><italic toggle="yes">Euro Surveillance</italic></source><year>2023</year><volume>28</volume><issue>12</issue><fpage>p. 2200772</fpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2023.28.12.2200772</pub-id><pub-id pub-id-type="pmcid">PMC10037659</pub-id><pub-id pub-id-type="pmid">36951783</pub-id></element-citation></ref><ref id="B106" content-type="article"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jessen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Boesecke</surname><given-names>C.</given-names></name></person-group><article-title>Monkeypox in Germany: Initial Clinical Observations</article-title><source><italic toggle="yes">Deutsches &#196;rzteblatt international</italic></source><year>2022</year><volume>119</volume><issue>33-34</issue><fpage>p. 551</fpage><pub-id pub-id-type="doi">10.3238/arztebl.m2022.0287</pub-id><pub-id pub-id-type="pmcid">PMC9743222</pub-id><pub-id pub-id-type="pmid">35912445</pub-id></element-citation></ref><ref id="B107" content-type="article"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogoina</surname><given-names>D.</given-names></name><name name-style="western"><surname>Iroezindu</surname><given-names>M.</given-names></name><name name-style="western"><surname>James</surname><given-names>H. I.</given-names></name><etal/></person-group><article-title>Clinical Course and Outcome of Human Monkeypox in Nigeria</article-title><source><italic toggle="yes">Clinical Infectious Diseases</italic></source><year>2020</year><volume>71</volume><issue>8</issue><fpage>e210</fpage><lpage>e214</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa143</pub-id><pub-id pub-id-type="pmid">32052029</pub-id></element-citation></ref><ref id="B108" content-type="book"><label>108</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Badenoch</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Conti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rengasamy</surname><given-names>E. R.</given-names></name><etal/></person-group><source><italic toggle="yes">Neurological and Psychiatric Presentations Associated with Human Monkeypox Virus Infection: A Systematic Review and Meta-Analysis</italic></source><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2022.101644</pub-id><pub-id pub-id-type="pmcid">PMC9533950</pub-id><pub-id pub-id-type="pmid">36246957</pub-id></element-citation></ref><ref id="B109" content-type="article"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pastula</surname><given-names>D. M.</given-names></name></person-group><article-title>Two Cases of Monkeypox-Associated Encephalomyelitis&#8212;Colorado and the District of Columbia, July&#8211;August 2022</article-title><source><italic toggle="yes">MMWR. Morbidity and Mortality Weekly Report</italic></source><year>2022</year><volume>71</volume><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7138e1</pub-id><pub-id pub-id-type="pmcid">PMC9531567</pub-id><pub-id pub-id-type="pmid">36136957</pub-id></element-citation></ref><ref id="B110" content-type="article"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandhi</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Padhi</surname><given-names>B. K.</given-names></name><etal/></person-group><article-title>Ophthalmic Manifestations of the Monkeypox Virus: a Systematic Review and Meta-Analysis</article-title><source><italic toggle="yes">Pathogens</italic></source><year>2023</year><volume>12</volume><issue>3</issue><fpage>p. 452</fpage><pub-id pub-id-type="doi">10.3390/pathogens12030452</pub-id><pub-id pub-id-type="pmcid">PMC10056031</pub-id><pub-id pub-id-type="pmid">36986374</pub-id></element-citation></ref><ref id="B111" content-type="article"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kolli</surname><given-names>S. T.</given-names></name><name name-style="western"><surname>Asuzu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The First Human to Have Necrotizing Pneumonia Secondary to Monkeypox Infection</article-title><source><italic toggle="yes">Chest</italic></source><year>2023</year><volume>164</volume><issue>4</issue><fpage>A1325</fpage><lpage>A1326</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2023.07.930</pub-id></element-citation></ref><ref id="B112" content-type="article"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollack</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kontorovich</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Fuster</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dec</surname><given-names>G. W.</given-names></name></person-group><article-title>Viral Myocarditis&#8212;Diagnosis, Treatment Options, and Current Controversies</article-title><source><italic toggle="yes">Nature Reviews Cardiology</italic></source><year>2015</year><volume>12</volume><issue>11</issue><fpage>670</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/nrcardio.2015.108</pub-id><pub-id pub-id-type="other">2-s2.0-84945477620</pub-id><pub-id pub-id-type="pmid">26194549</pub-id></element-citation></ref><ref id="B113" content-type="article"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dumont</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guilhou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gerin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Myocarditis in Monkeypox-Infected Patients: a Case Series</article-title><source><italic toggle="yes">Clinical Microbiology and Infection</italic></source><year>2023</year><volume>29</volume><issue>3</issue><fpage>p. 390-e5</fpage><pub-id pub-id-type="doi">10.1016/j.cmi.2022.12.001</pub-id><pub-id pub-id-type="pmcid">PMC9735378</pub-id><pub-id pub-id-type="pmid">36509373</pub-id></element-citation></ref><ref id="B114" content-type="article"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brouillard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Valin-Thorburn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Provost</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Monkeypox Associated Myocarditis: a Case Report</article-title><source><italic toggle="yes">IDCases</italic></source><year>2022</year><volume>30</volume><fpage>p. e01628</fpage><pub-id pub-id-type="doi">10.1016/j.idcr.2022.e01628</pub-id><pub-id pub-id-type="pmcid">PMC9622465</pub-id><pub-id pub-id-type="pmid">36345425</pub-id></element-citation></ref><ref id="B115" content-type="article"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaiswal</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sultana</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lahori</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Monkeypox-induced Myocarditis: a Systematic Review</article-title><source><italic toggle="yes">Current Problems in Cardiology</italic></source><year>2023</year><volume>48</volume><issue>5</issue><fpage>p. 101611</fpage><pub-id pub-id-type="doi">10.1016/j.cpcardiol.2023.101611</pub-id><pub-id pub-id-type="pmcid">PMC9883211</pub-id><pub-id pub-id-type="pmid">36716982</pub-id></element-citation></ref><ref id="B116" content-type="article"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tchoubou</surname><given-names>T.</given-names></name><name name-style="western"><surname>El-Hosni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dollat</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Acute Respiratory Distress Syndrome Due to Monkeypox Virus</article-title><source><italic toggle="yes">European Journal of Case Reports in Internal Medicine</italic></source><year>2023</year><volume>10</volume><issue>11</issue><pub-id pub-id-type="doi">10.12890/2023_004126</pub-id><pub-id pub-id-type="pmcid">PMC10619529</pub-id><pub-id pub-id-type="pmid">37920221</pub-id></element-citation></ref><ref id="B117" content-type="article"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maredia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sartori-Valinotti</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Ranganath</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tosh</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>O&#8217;Horo</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>A. S.</given-names></name></person-group><article-title>Supportive Care Management Recommendations for Mucocutaneous Manifestations of Monkeypox Infection</article-title><source><italic toggle="yes">Mayo Clinic Proceedings</italic></source><year>2023</year><volume>98</volume><issue>6</issue><fpage>828</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">37125977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mayocp.2023.01.019</pub-id><pub-id pub-id-type="pmcid">PMC10148669</pub-id></element-citation></ref><ref id="B118" content-type="article"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zovi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferrara</surname><given-names>F.</given-names></name><name name-style="western"><surname>Langella</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vitiello</surname><given-names>A.</given-names></name></person-group><article-title>Pharmacological Agents with Antiviral Activity against Monkeypox Infection</article-title><source><italic toggle="yes">International Journal of Molecular Sciences</italic></source><year>2022</year><volume>23</volume><issue>24</issue><fpage>p. 15941</fpage><pub-id pub-id-type="doi">10.3390/ijms232415941</pub-id><pub-id pub-id-type="pmcid">PMC9784635</pub-id><pub-id pub-id-type="pmid">36555584</pub-id></element-citation></ref><ref id="B119" content-type="article"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chinsangaram</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bolken</surname><given-names>T. C.</given-names></name><etal/></person-group><article-title>Safety and Pharmacokinetics of the Antiorthopoxvirus Compound ST-246 Following Repeat Oral Dosing in Healthy Adult Subjects</article-title><source><italic toggle="yes">Antimicrobial Agents and Chemotherapy</italic></source><year>2010</year><volume>54</volume><issue>6</issue><fpage>2560</fpage><lpage>2566</lpage><pub-id pub-id-type="doi">10.1128/aac.01689-09</pub-id><pub-id pub-id-type="other">2-s2.0-77952642017</pub-id><pub-id pub-id-type="pmid">20385870</pub-id><pub-id pub-id-type="pmcid">PMC2876426</pub-id></element-citation></ref><ref id="B120" content-type="article"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duraffour</surname><given-names>S.</given-names></name><name name-style="western"><surname>Snoeck</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Vos</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Activity of the Anti-orthopoxvirus Compound ST-246 against Vaccinia, Cowpox and Camelpox Viruses in Cell Monolayers and Organotypic Raft Cultures</article-title><source><italic toggle="yes">Antiviral Therapy</italic></source><year>2007</year><volume>12</volume><issue>8</issue><fpage>1205</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1177/135965350701200802</pub-id><pub-id pub-id-type="pmid">18240860</pub-id></element-citation></ref><ref id="B121" content-type="article"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Grosenbach</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Honeychurch</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Long</surname><given-names>P. G.</given-names></name><name name-style="western"><surname>Hruby</surname><given-names>D. E.</given-names></name></person-group><article-title>Overview of the Regulatory Approval of Tecovirimat Intravenous Formulation for Treatment of Smallpox: Potential Impact on Smallpox Outbreak Response Capabilities, and Future Tecovirimat Development Potential</article-title><source><italic toggle="yes">Expert Review of Anti-infective Therapy</italic></source><year>2023</year><volume>21</volume><issue>3</issue><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1080/14787210.2023.2170350</pub-id><pub-id pub-id-type="pmid">36728515</pub-id><pub-id pub-id-type="pmcid">PMC10054055</pub-id></element-citation></ref><ref id="B122" content-type="article"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegrist</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Sassine</surname><given-names>J.</given-names></name></person-group><article-title>Antivirals with Activity against Mpox: a Clinically Oriented Review</article-title><source><italic toggle="yes">Clinical Infectious Diseases</italic></source><year>2023</year><volume>76</volume><issue>1</issue><fpage>155</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac622</pub-id><pub-id pub-id-type="pmid">35904001</pub-id><pub-id pub-id-type="pmcid">PMC9825831</pub-id></element-citation></ref><ref id="B123" content-type="article"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grosenbach</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Honeychurch</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>E. A.</given-names></name><etal/></person-group><article-title>Oral Tecovirimat for the Treatment of Smallpox</article-title><source><italic toggle="yes">New England Journal of Medicine</italic></source><year>2018</year><volume>379</volume><issue>1</issue><fpage>44</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1705688</pub-id><pub-id pub-id-type="other">2-s2.0-85049634143</pub-id><pub-id pub-id-type="pmid">29972742</pub-id><pub-id pub-id-type="pmcid">PMC6086581</pub-id></element-citation></ref><ref id="B124" content-type="article"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huggins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Goff</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Nonhuman Primates Are Protected from Smallpox Virus or Monkeypox Virus Challenges by the Antiviral Drug ST-246</article-title><source><italic toggle="yes">Antimicrobial Agents and Chemotherapy</italic></source><year>2009</year><volume>53</volume><issue>6</issue><fpage>2620</fpage><lpage>2625</lpage><pub-id pub-id-type="doi">10.1128/aac.00021-09</pub-id><pub-id pub-id-type="other">2-s2.0-67049136160</pub-id><pub-id pub-id-type="pmid">19349521</pub-id><pub-id pub-id-type="pmcid">PMC2687232</pub-id></element-citation></ref><ref id="B125" content-type="article"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Self</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Effective Antiviral Treatment of Systemic Orthopoxvirus Disease: ST-246 Treatment of Prairie Dogs Infected with Monkeypox Virus</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2011</year><volume>85</volume><issue>17</issue><fpage>9176</fpage><lpage>9187</lpage><pub-id pub-id-type="doi">10.1128/jvi.02173-10</pub-id><pub-id pub-id-type="other">2-s2.0-80052279730</pub-id><pub-id pub-id-type="pmid">21697474</pub-id><pub-id pub-id-type="pmcid">PMC3165798</pub-id></element-citation></ref><ref id="B126" content-type="article"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goff</surname><given-names>A.</given-names></name><name name-style="western"><surname>Frimm</surname><given-names>A.</given-names></name><etal/></person-group><article-title>ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose Justification</article-title><source><italic toggle="yes">Antimicrobial Agents and Chemotherapy</italic></source><year>2009</year><volume>53</volume><issue>5</issue><fpage>1817</fpage><lpage>1822</lpage><pub-id pub-id-type="doi">10.1128/aac.01596-08</pub-id><pub-id pub-id-type="other">2-s2.0-66149119341</pub-id><pub-id pub-id-type="pmid">19223621</pub-id><pub-id pub-id-type="pmcid">PMC2681496</pub-id></element-citation></ref><ref id="B127" content-type="article"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plosker</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Noble</surname><given-names>S.</given-names></name></person-group><article-title>Cidofovir: a Review of its Use in Cytomegalovirus Retinitis in Patients with AIDS</article-title><source><italic toggle="yes">Drugs</italic></source><year>1999</year><volume>58</volume><fpage>325</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.2165/00003495-199958020-00015</pub-id><pub-id pub-id-type="other">2-s2.0-0032815308</pub-id><pub-id pub-id-type="pmid">10473024</pub-id></element-citation></ref><ref id="B128" content-type="article"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>R. O.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huggins</surname><given-names>J. W.</given-names></name></person-group><article-title>Potential Antiviral Therapeutics for Smallpox, Monkeypox and Other Orthopoxvirus Infections</article-title><source><italic toggle="yes">Antiviral Research</italic></source><year>2003</year><volume>57</volume><issue>1-2</issue><fpage>13</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">12615299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0166-3542(02)00196-1</pub-id><pub-id pub-id-type="pmcid">PMC9533837</pub-id></element-citation></ref><ref id="B129" content-type="book"><label>129</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>R. O.</given-names></name></person-group><source><italic toggle="yes">Clinical Management and Infection Prevention and Control for Monkeypox: Interim Rapid Response Guidance</italic></source><year>2022</year><publisher-loc>&#8207;</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="B130" content-type="article"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adhisaya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hariharan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mugeshwaran</surname><given-names>R. N.</given-names></name><name name-style="western"><surname>Sriram</surname><given-names>A.</given-names></name></person-group><article-title>OUTBREAK OF NOVEL HUMANMONKEY POX VIRUS-A COMPREHENSIVE REVIEW</article-title><source><italic toggle="yes">NeuroQuantology</italic></source><year>2023</year><volume>21</volume><issue>6</issue><fpage>p. 1558</fpage><pub-id pub-id-type="doi">10.48047/nq.2023.21.6.NQ23156</pub-id></element-citation></ref><ref id="B131" content-type="article"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smee</surname><given-names>D. F.</given-names></name><name name-style="western"><surname>Sidwell</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Kefauver</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huggins</surname><given-names>J. W.</given-names></name></person-group><article-title>Characterization of Wild-type and Cidofovir-Resistant Strains of Camelpox, Cowpox, Monkeypox, and Vaccinia Viruses</article-title><source><italic toggle="yes">Antimicrobial Agents and Chemotherapy</italic></source><year>2002</year><volume>46</volume><issue>5</issue><fpage>1329</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1128/aac.46.5.1329-1335.2002</pub-id><pub-id pub-id-type="other">2-s2.0-0036239724</pub-id><pub-id pub-id-type="pmid">11959564</pub-id><pub-id pub-id-type="pmcid">PMC127179</pub-id></element-citation></ref><ref id="B132" content-type="article"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farlow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ichou</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Huggins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>S.</given-names></name></person-group><article-title>Comparative Whole Genome Sequence Analysis of Wild-type and Cidofovir-Resistant Monkeypoxvirus</article-title><source><italic toggle="yes">Virology Journal</italic></source><year>2010</year><volume>7</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1186/1743-422X-7-110</pub-id><pub-id pub-id-type="other">2-s2.0-77952713290</pub-id><pub-id pub-id-type="pmid">20509894</pub-id><pub-id pub-id-type="pmcid">PMC2890524</pub-id></element-citation></ref><ref id="B133" content-type="article"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrei</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gammon</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Fiten</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Cidofovir Resistance in Vaccinia Virus Is Linked to Diminished Virulencein Mice</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2006</year><volume>80</volume><issue>19</issue><fpage>9391</fpage><lpage>9401</lpage><pub-id pub-id-type="doi">10.1128/jvi.00605-06</pub-id><pub-id pub-id-type="other">2-s2.0-33748946630</pub-id><pub-id pub-id-type="pmid">16973545</pub-id><pub-id pub-id-type="pmcid">PMC1617232</pub-id></element-citation></ref><ref id="B134" content-type="misc"><label>134</label><element-citation publication-type="other"><article-title>Chimerix. Tembexa (Brincidofovir) [package Insert]</article-title><year>2021</year></element-citation></ref><ref id="B135" content-type="article"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quenelle</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Prichard</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Keith</surname><given-names>K. A.</given-names></name><etal/></person-group><article-title>Synergistic Efficacy of the Combination of ST-246 with CMX001 against Orthopoxviruses</article-title><source><italic toggle="yes">Antimicrobial Agents and Chemotherapy</italic></source><year>2007</year><volume>51</volume><issue>11</issue><fpage>4118</fpage><lpage>4124</lpage><pub-id pub-id-type="doi">10.1128/aac.00762-07</pub-id><pub-id pub-id-type="other">2-s2.0-35848968505</pub-id><pub-id pub-id-type="pmid">17724153</pub-id><pub-id pub-id-type="pmcid">PMC2151443</pub-id></element-citation></ref><ref id="B136" content-type="article"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hostetler</surname><given-names>K. Y.</given-names></name></person-group><article-title>Alkoxyalkyl Prodrugs of Acyclic Nucleoside Phosphonates Enhance Oral Antiviral Activity and Reduce Toxicity: Current State of the Art</article-title><source><italic toggle="yes">Antiviral Research</italic></source><year>2009</year><volume>82</volume><issue>2</issue><fpage>A84</fpage><lpage>A98</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2009.01.005</pub-id><pub-id pub-id-type="other">2-s2.0-67349157073</pub-id><pub-id pub-id-type="pmid">19425198</pub-id><pub-id pub-id-type="pmcid">PMC2768545</pub-id></element-citation></ref><ref id="B137" content-type="article"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aldern</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Ciesla</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Winegarden</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Hostetler</surname><given-names>K. Y.</given-names></name></person-group><article-title>Increased Antiviral Activity of 1-O-Hexadecyloxypropyl-[2-14c] Cidofovir in MRC-5 Human Lung Fibroblasts Is Explained by Unique Cellular Uptake and Metabolism</article-title><source><italic toggle="yes">Molecular Pharmacology</italic></source><year>2003</year><volume>63</volume><issue>3</issue><fpage>678</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1124/mol.63.3.678</pub-id><pub-id pub-id-type="other">2-s2.0-0037333556</pub-id><pub-id pub-id-type="pmid">12606777</pub-id></element-citation></ref><ref id="B138" content-type="article"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciesla</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Trahan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>W. B.</given-names></name><etal/></person-group><article-title>Esterification of Cidofovir with Alkoxyalkanols Increases Oral Bioavailability and Diminishes Drug Accumulation in Kidney</article-title><source><italic toggle="yes">Antiviral Research</italic></source><year>2003</year><volume>59</volume><issue>3</issue><fpage>163</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/S0166-3542(03)00110-4</pub-id><pub-id pub-id-type="other">2-s2.0-0042632872</pub-id><pub-id pub-id-type="pmid">12927306</pub-id></element-citation></ref><ref id="B139" content-type="article"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chittick</surname><given-names>G.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brundage</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>W. G.</given-names></name></person-group><article-title>Short-term Clinical Safety Profile of Brincidofovir: A Favorable Benefit&#8211;Risk Proposition in the Treatment of Smallpox</article-title><source><italic toggle="yes">Antiviral Research</italic></source><year>2017</year><volume>143</volume><fpage>269</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2017.01.009</pub-id><pub-id pub-id-type="other">2-s2.0-85015628196</pub-id><pub-id pub-id-type="pmid">28093339</pub-id></element-citation></ref><ref id="B140" content-type="article"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The Evolving Epidemiology of Monkeypox Virus</article-title><source><italic toggle="yes">Cytokine &amp; Growth Factor Reviews</italic></source><year>2022</year><volume>68</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2022.10.002</pub-id><pub-id pub-id-type="pmid">36244878</pub-id><pub-id pub-id-type="pmcid">PMC9547435</pub-id></element-citation></ref><ref id="B141" content-type="article"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Painter</surname><given-names>W.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trost</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Godkin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lampert</surname><given-names>B.</given-names></name><name name-style="western"><surname>Painter</surname><given-names>G.</given-names></name></person-group><article-title>First Pharmacokinetic and Safety Study in Humans of the Novel Lipid Antiviral Conjugate CMX001, a Broad-Spectrum Oral Drug Active against Double-Stranded DNA Viruses</article-title><source><italic toggle="yes">Antimicrobial Agents and Chemotherapy</italic></source><year>2012</year><volume>56</volume><issue>5</issue><fpage>2726</fpage><lpage>2734</lpage><pub-id pub-id-type="doi">10.1128/aac.05983-11</pub-id><pub-id pub-id-type="other">2-s2.0-84860188140</pub-id><pub-id pub-id-type="pmid">22391537</pub-id><pub-id pub-id-type="pmcid">PMC3346600</pub-id></element-citation></ref><ref id="B142" content-type="article"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghaseminia</surname><given-names>M.</given-names></name></person-group><article-title>Preventing Monkeypox Outbreaks: Focus on Diagnosis, Care, Treatment, and Vaccination</article-title><source><italic toggle="yes">Journal of clinical and translational science</italic></source><year>2023</year><volume>7</volume><issue>1</issue><fpage>p. e60</fpage><pub-id pub-id-type="doi">10.1017/cts.2023.11</pub-id><pub-id pub-id-type="pmcid">PMC10052442</pub-id><pub-id pub-id-type="pmid">37008622</pub-id></element-citation></ref><ref id="B143" content-type="article"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edghill-Smith</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Golding</surname><given-names>H.</given-names></name><name name-style="western"><surname>Manischewitz</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Smallpox Vaccine&#8211;Induced Antibodies Are Necessary and Sufficient for Protection against Monkeypox Virus</article-title><source><italic toggle="yes">Nature medicine</italic></source><year>2005</year><volume>11</volume><issue>7</issue><fpage>740</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1038/nm1261</pub-id><pub-id pub-id-type="other">2-s2.0-22544457889</pub-id><pub-id pub-id-type="pmid">15951823</pub-id></element-citation></ref><ref id="B144" content-type="article"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Realegeno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pant</surname><given-names>A.</given-names></name><name name-style="western"><surname>Satheshkumar</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name></person-group><article-title>Suppression of Poxvirus Replication by Resveratrol</article-title><source><italic toggle="yes">Frontiers in Microbiology</italic></source><year>2017</year><volume>8</volume><fpage>p. 2196</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.02196</pub-id><pub-id pub-id-type="other">2-s2.0-85034627511</pub-id><pub-id pub-id-type="pmcid">PMC5698801</pub-id><pub-id pub-id-type="pmid">29204136</pub-id></element-citation></ref><ref id="B145" content-type="article"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Connor</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Ruthel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Goff</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>L. E.</given-names></name></person-group><article-title>In Vitro Inhibition of Monkeypox Virus Production and Spread by Interferon-<italic toggle="yes">&#946;</italic></article-title><source><italic toggle="yes">Virology Journal</italic></source><year>2012</year><volume>9</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1186/1743-422X-9-5</pub-id><pub-id pub-id-type="other">2-s2.0-84855443562</pub-id><pub-id pub-id-type="pmid">22225589</pub-id><pub-id pub-id-type="pmcid">PMC3284473</pub-id></element-citation></ref><ref id="B146" content-type="article"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Aggregation&#8208;induced Emission&#8208;based Macrophage&#8208;like Nanoparticles for Targeted Photothermal Therapy and Virus Transmission Blockage in Monkeypox</article-title><source><italic toggle="yes">Advanced Materials</italic></source><year>2024</year><volume>36</volume><issue>9</issue><fpage>p. 2305378</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202305378</pub-id><pub-id pub-id-type="pmid">37931029</pub-id></element-citation></ref><ref id="B147" content-type="article"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hernaez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Alcam&#237;</surname><given-names>A.</given-names></name></person-group><article-title>Poxvirus Immune Evasion</article-title><source><italic toggle="yes">Annual Review of Immunology</italic></source><year>2024</year><volume>42</volume><issue>1</issue><fpage>551</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-090222-110227</pub-id><pub-id pub-id-type="pmid">38941604</pub-id></element-citation></ref><ref id="B148" content-type="article"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lalani</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mossman</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The Purified Myxoma Virus Gamma Interferon Receptor Homolog M-T7 Interacts with the Heparin-Binding Domains of Chemokines</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>1997</year><volume>71</volume><issue>6</issue><fpage>4356</fpage><lpage>4363</lpage><pub-id pub-id-type="doi">10.1128/jvi.71.6.4356-4363.1997</pub-id><pub-id pub-id-type="pmid">9151824</pub-id><pub-id pub-id-type="pmcid">PMC191652</pub-id></element-citation></ref><ref id="B149" content-type="article"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shchelkunov</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Totmenin</surname><given-names>A. V.</given-names></name><name name-style="western"><surname>Safronov</surname><given-names>P. F.</given-names></name><etal/></person-group><article-title>Analysis of the Monkeypox Virus Genome</article-title><source><italic toggle="yes">Virology</italic></source><year>2002</year><volume>297</volume><issue>2</issue><fpage>172</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1006/viro.2002.1446</pub-id><pub-id pub-id-type="other">2-s2.0-0036308578</pub-id><pub-id pub-id-type="pmid">12083817</pub-id><pub-id pub-id-type="pmcid">PMC9534300</pub-id></element-citation></ref><ref id="B150" content-type="article"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jezek</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Marennikova</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Mutumbo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakano</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Paluku</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Szczeniowski</surname><given-names>M.</given-names></name></person-group><article-title>Human Monkeypox: a Study of 2,510 Contacts of 214 Patients</article-title><source><italic toggle="yes">Journal of Infectious Diseases</italic></source><year>1986</year><volume>154</volume><issue>4</issue><fpage>551</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1093/infdis/154.4.551</pub-id><pub-id pub-id-type="other">2-s2.0-0022447023</pub-id><pub-id pub-id-type="pmid">3018091</pub-id></element-citation></ref><ref id="B151" content-type="article"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collier</surname><given-names>L. H.</given-names></name></person-group><article-title>The Development of a Stable Smallpox Vaccine</article-title><source><italic toggle="yes">Epidemiology and Infection</italic></source><year>1955</year><volume>53</volume><issue>1</issue><fpage>76</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1017/S002217240000053X</pub-id><pub-id pub-id-type="other">2-s2.0-0003023117</pub-id><pub-id pub-id-type="pmcid">PMC2217800</pub-id><pub-id pub-id-type="pmid">14367805</pub-id></element-citation></ref><ref id="B152" content-type="article"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melamed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Israely</surname><given-names>T.</given-names></name><name name-style="western"><surname>Paran</surname><given-names>N.</given-names></name></person-group><article-title>Challenges and Achievements in Prevention and Treatment of Smallpox</article-title><source><italic toggle="yes">Vaccines</italic></source><year>2018</year><volume>6</volume><issue>1</issue><fpage>p. 8</fpage><pub-id pub-id-type="doi">10.3390/vaccines6010008</pub-id><pub-id pub-id-type="other">2-s2.0-85041966077</pub-id><pub-id pub-id-type="pmid">29382130</pub-id><pub-id pub-id-type="pmcid">PMC5874649</pub-id></element-citation></ref><ref id="B153" content-type="misc"><label>153</label><element-citation publication-type="other"><collab>FDA</collab><article-title>Approval Letter-ACAM2000 2007</article-title><year>2007</year></element-citation></ref><ref id="B154" content-type="book"><label>154</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Frey</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>F. K.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>J. S.</given-names></name><etal/></person-group><source><italic toggle="yes">Comparison of the Safety and Immunogenicity of ACAM1000, ACAM2000 and Dryvax&#174; in Healthy Vaccinia-Naive Adults</italic></source><year>2009</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2008.11.079</pub-id><pub-id pub-id-type="pmid">19071184</pub-id></element-citation></ref><ref id="B155" content-type="article"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelaal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lashin</surname><given-names>B. I.</given-names></name><etal/></person-group><article-title>Preventing the Next Pandemic: Is Live Vaccine Efficacious against Monkeypox, or Is There a Need for Killed Virus and mRNA Vaccines?</article-title><source><italic toggle="yes">Vaccines</italic></source><year>2022</year><volume>10</volume><issue>9</issue><fpage>p. 1419</fpage><pub-id pub-id-type="doi">10.3390/vaccines10091419</pub-id><pub-id pub-id-type="pmid">36146497</pub-id><pub-id pub-id-type="pmcid">PMC9500691</pub-id></element-citation></ref><ref id="B156" content-type="article"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassimatis</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Atwood</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Engler</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Linz</surname><given-names>P. E.</given-names></name><name name-style="western"><surname>Grabenstein</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Vernalis</surname><given-names>M. N.</given-names></name></person-group><article-title>Smallpox Vaccination and Myopericarditis: a Clinical Review</article-title><source><italic toggle="yes">Journal of the American College of Cardiology</italic></source><year>2004</year><volume>43</volume><issue>9</issue><fpage>1503</fpage><lpage>1510</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2003.11.053</pub-id><pub-id pub-id-type="other">2-s2.0-2342440009</pub-id><pub-id pub-id-type="pmid">15120802</pub-id></element-citation></ref><ref id="B157" content-type="article"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yokote</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shinmura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kanehara</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Vaccinia Virus Strain LC16m8 Defective in the B5R Gene Keeps Strong Protection Comparable to its Parental Strain Lister in Immunodeficient Mice</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2015</year><volume>33</volume><issue>45</issue><fpage>6112</fpage><lpage>6119</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.07.076</pub-id><pub-id pub-id-type="other">2-s2.0-84947486478</pub-id><pub-id pub-id-type="pmid">26241947</pub-id></element-citation></ref><ref id="B158" content-type="article"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poland</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Tosh</surname><given-names>P. K.</given-names></name></person-group><article-title>Prevention of Monkeypox with Vaccines: a Rapid Review</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2022</year><volume>22</volume><issue>12</issue><fpage>e349</fpage><lpage>e358</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00574-6</pub-id><pub-id pub-id-type="pmid">36116460</pub-id><pub-id pub-id-type="pmcid">PMC9628950</pub-id></element-citation></ref><ref id="B159" content-type="article"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomita</surname><given-names>N.</given-names></name><name name-style="western"><surname>Terada-Hirashima</surname><given-names>J.</given-names></name><name name-style="western"><surname>Uemura</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>An Open-Label, Non-randomized Study Investigating the Safety and Efficacy of Smallpox Vaccine, LC16, as Post-exposure Prophylaxis for Mpox</article-title><source><italic toggle="yes">Human Vaccines &amp; Immunotherapeutics</italic></source><year>2023</year><volume>19</volume><issue>2</issue><fpage>p. 2242219</fpage><pub-id pub-id-type="doi">10.1080/21645515.2023.2242219</pub-id><pub-id pub-id-type="pmcid">PMC10416734</pub-id><pub-id pub-id-type="pmid">37559375</pub-id></element-citation></ref><ref id="B160" content-type="misc"><label>160</label><element-citation publication-type="other"><article-title>JYNNEOS: Highlights of Prescribing Information: US Food &amp; Drug Administration</article-title><year>2019</year><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/131078/download" ext-link-type="uri">https://www.fda.gov/media/131078/download</ext-link></comment></element-citation></ref><ref id="B161" content-type="article"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Humayun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baig</surname><given-names>E.</given-names></name><etal/></person-group><article-title>FDA&#8217;s Authorized &#8220;JYNNEOS&#8221; Vaccine for Counteracting Monkeypox Global Public Health Emergency; an Update&#8211;Correspondence</article-title><source><italic toggle="yes">International Journal of Surgery</italic></source><year>2022</year><volume>107</volume><fpage>p. 106971</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijsu.2022.106971</pub-id><pub-id pub-id-type="pmcid">PMC9617681</pub-id><pub-id pub-id-type="pmid">36330988</pub-id></element-citation></ref><ref id="B162" content-type="article"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maruggi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ulmer</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name></person-group><article-title>mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases</article-title><source><italic toggle="yes">Molecular Therapy</italic></source><year>2019</year><volume>27</volume><issue>4</issue><fpage>757</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.01.020</pub-id><pub-id pub-id-type="other">2-s2.0-85061801116</pub-id><pub-id pub-id-type="pmid">30803823</pub-id><pub-id pub-id-type="pmcid">PMC6453507</pub-id></element-citation></ref><ref id="B163" content-type="article"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brito</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Kommareddy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maione</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Self-amplifying mRNA Vaccines</article-title><source><italic toggle="yes">Advances in Genetics</italic></source><year>2015</year><volume>89</volume><fpage>179</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/bs.adgen.2014.10.005</pub-id><pub-id pub-id-type="other">2-s2.0-84921498605</pub-id><pub-id pub-id-type="pmid">25620012</pub-id></element-citation></ref><ref id="B164" content-type="article"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lazzaro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Habbeddine</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Unmodified mRNA in LNPs Constitutes a Competitive Technology for Prophylactic Vaccines</article-title><source><italic toggle="yes">Npj Vaccines</italic></source><year>2017</year><volume>2</volume><issue>1</issue><fpage>p. 29</fpage><pub-id pub-id-type="doi">10.1038/s41541-017-0032-6</pub-id><pub-id pub-id-type="other">2-s2.0-85042232690</pub-id><pub-id pub-id-type="pmid">29263884</pub-id><pub-id pub-id-type="pmcid">PMC5648897</pub-id></element-citation></ref><ref id="B165" content-type="incollection"><label>165</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Maruggi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ulmer</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name></person-group><article-title>Self-amplifying mRNA-Based Vaccine Technology and its Mode of Action</article-title><source><italic toggle="yes">mRNA Vaccines</italic></source><year>2021</year><publisher-loc>Cham</publisher-loc><publisher-name>Springer International Publishing</publisher-name><fpage>31</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1007/82_2021_233</pub-id><pub-id pub-id-type="pmid">33861374</pub-id></element-citation></ref><ref id="B166" content-type="article"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luisi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Morabito</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Burgomaster</surname><given-names>K. E.</given-names></name><etal/></person-group><article-title>Development of a Potent Zika Virus Vaccine Using Self-Amplifying Messenger RNA</article-title><source><italic toggle="yes">Science Advances</italic></source><year>2020</year><volume>6</volume><issue>32</issue><fpage>p. eaba5068</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.aba5068</pub-id><pub-id pub-id-type="pmcid">PMC7413734</pub-id><pub-id pub-id-type="pmid">32821824</pub-id></element-citation></ref><ref id="B167" content-type="article"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maruggi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chiarot</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giovani</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Immunogenicity and Protective Efficacy Induced by Self-Amplifying mRNA Vaccines Encoding Bacterial Antigens</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2017</year><volume>35</volume><issue>2</issue><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.040</pub-id><pub-id pub-id-type="other">2-s2.0-85006983568</pub-id><pub-id pub-id-type="pmid">27939014</pub-id></element-citation></ref><ref id="B168" content-type="article"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Induction of Protective Immunity against Toxoplasma Gondii in Mice by Nucleoside Triphosphate Hydrolase-II (NTPase-II) Self-Amplifying RNA Vaccine Encapsulated in Lipid Nanoparticle (LNP)</article-title><source><italic toggle="yes">Frontiers in Microbiology</italic></source><year>2017</year><volume>8</volume><fpage>p. 605</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.00605</pub-id><pub-id pub-id-type="other">2-s2.0-85018414285</pub-id><pub-id pub-id-type="pmcid">PMC5380742</pub-id><pub-id pub-id-type="pmid">28424680</pub-id></element-citation></ref><ref id="B169" content-type="article"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erasmus</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Archer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fuerte-Stone</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection</article-title><source><italic toggle="yes">Molecular therapy Methods &amp; clinical development</italic></source><year>2020</year><volume>18</volume><fpage>402</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2020.06.011</pub-id><pub-id pub-id-type="pmid">32695842</pub-id><pub-id pub-id-type="pmcid">PMC7363633</pub-id></element-citation></ref><ref id="B170" content-type="article"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blakney</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Ip</surname><given-names>S.</given-names></name><name name-style="western"><surname>Geall</surname><given-names>A. J.</given-names></name></person-group><article-title>An Update on Self-Amplifying mRNA Vaccine Development</article-title><source><italic toggle="yes">Vaccines</italic></source><year>2021</year><volume>9</volume><issue>2</issue><fpage>p. 97</fpage><pub-id pub-id-type="doi">10.3390/vaccines9020097</pub-id><pub-id pub-id-type="pmcid">PMC7911542</pub-id><pub-id pub-id-type="pmid">33525396</pub-id></element-citation></ref><ref id="B171" content-type="article"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Monkeypox Virus Quadrivalent mRNA Vaccine Induces Immune Response and Protects against Vaccinia Virus</article-title><source><italic toggle="yes">Signal Transduction and Targeted Therapy</italic></source><year>2023</year><volume>8</volume><issue>1</issue><fpage>p. 172</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01432-5</pub-id><pub-id pub-id-type="pmid">37117161</pub-id><pub-id pub-id-type="pmcid">PMC10144886</pub-id></element-citation></ref><ref id="B172" content-type="article"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shantier</surname><given-names>S. W.</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>M. I.</given-names></name><name name-style="western"><surname>Abdelmoneim</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Fadl</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Elbager</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Makhawi</surname><given-names>A. M.</given-names></name></person-group><article-title>Novel Multi Epitope-Based Vaccine against Monkeypox Virus: Vaccinomic Approach</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2022</year><volume>12</volume><issue>1</issue><fpage>p. 15983</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-20397-z</pub-id><pub-id pub-id-type="pmcid">PMC9510130</pub-id><pub-id pub-id-type="pmid">36156077</pub-id></element-citation></ref><ref id="B173" content-type="article"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gouda</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sama</surname><given-names>N. U.</given-names></name><name name-style="western"><surname>Al-Waakid</surname><given-names>G.</given-names></name><name name-style="western"><surname>Humayun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jhanjhi</surname><given-names>N. Z.</given-names></name></person-group><article-title>Detection of Skin Cancer Based on Skin Lesion Images Using Deep Learning</article-title><source><italic toggle="yes">Healthcare</italic></source><year>2022</year><month>June</month><volume>10</volume><issue>7</issue><fpage>p. 1183</fpage><pub-id pub-id-type="doi">10.3390/healthcare10071183</pub-id><pub-id pub-id-type="pmcid">PMC9324455</pub-id><pub-id pub-id-type="pmid">35885710</pub-id></element-citation></ref><ref id="B174" content-type="article"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shafi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Din</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><etal/></person-group><article-title>An Effective Method for Lung Cancer Diagnosis from Ct Scan Using Deep Learning-Based Support Vector Network</article-title><source><italic toggle="yes">Cancers</italic></source><year>2022</year><volume>14</volume><issue>21</issue><fpage>p. 5457</fpage><pub-id pub-id-type="doi">10.3390/cancers14215457</pub-id><pub-id pub-id-type="pmcid">PMC9657078</pub-id><pub-id pub-id-type="pmid">36358875</pub-id></element-citation></ref><ref id="B175" content-type="article"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fritz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fritz</surname><given-names>J.</given-names></name></person-group><article-title>Artificial Intelligence for MRI Diagnosis of Joints: a Scoping Review of the Current State-Of-The-Art of Deep Learning-Based Approaches</article-title><source><italic toggle="yes">Skeletal Radiology</italic></source><year>2022</year><volume>51</volume><issue>2</issue><fpage>315</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">34467424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00256-021-03830-8</pub-id><pub-id pub-id-type="pmcid">PMC8692303</pub-id></element-citation></ref><ref id="B176" content-type="inproceedings"><label>176</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name></person-group><article-title>Deep Residual Learning for Image Recognition</article-title><conf-name>Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition</conf-name><conf-date>March 2016</conf-date><publisher-name>&#8207;</publisher-name><fpage>770</fpage><lpage>778</lpage></element-citation></ref><ref id="B177" content-type="misc"><label>177</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Dosovitskiy</surname><given-names>A.</given-names></name></person-group><article-title>An Image Is Worth 16x16 Words: Transformers for Image Recognition at Scale</article-title><year>2020</year></element-citation></ref><ref id="B178" content-type="article"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaturvedi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodiah</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kretzschmar</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Estimating the Relative Importance of Epidemiological and Behavioural Parameters for Epidemic Mpox Transmission: a Modelling Study</article-title><source><italic toggle="yes">BMC Medicine</italic></source><year>2024</year><volume>22</volume><issue>1</issue><fpage>p. 297</fpage><pub-id pub-id-type="doi">10.1186/s12916-024-03515-8</pub-id><pub-id pub-id-type="pmcid">PMC11256368</pub-id><pub-id pub-id-type="pmid">39020322</pub-id></element-citation></ref><ref id="B179" content-type="article"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hopkins</surname><given-names>A. L.</given-names></name></person-group><article-title>Network Pharmacology: the Next Paradigm in Drug Discovery</article-title><source><italic toggle="yes">Nature Chemical Biology</italic></source><year>2008</year><volume>4</volume><issue>11</issue><fpage>682</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1038/nchembio.118</pub-id><pub-id pub-id-type="other">2-s2.0-54249155522</pub-id><pub-id pub-id-type="pmid">18936753</pub-id></element-citation></ref><ref id="B180" content-type="article"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Abdulqadir</surname><given-names>S. O.</given-names></name><name name-style="western"><surname>Omar</surname><given-names>R. M.</given-names></name><etal/></person-group><article-title>Knowledge, Attitude and Worry in the Kurdistan Region of Iraq during the Mpox (Monkeypox) Outbreak in 2022: an Online Cross-Sectional Study</article-title><source><italic toggle="yes">Vaccines</italic></source><year>2023</year><volume>11</volume><issue>3</issue><fpage>p. 610</fpage><pub-id pub-id-type="doi">10.3390/vaccines11030610</pub-id><pub-id pub-id-type="pmcid">PMC10054073</pub-id><pub-id pub-id-type="pmid">36992194</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Flowchart of the study selection process.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JTM2024-6688914.001.jpg"/></fig><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>The reproduction cycle of the MPOX and the activation sites of different therapeutics against it; EVs, extracellular virions; MVs, mature virions; VIG, Vaccinia Immune Globulin.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JTM2024-6688914.002.jpg"/></fig><fig position="float" id="fig3" orientation="portrait"><label>Figure 3</label><caption><p>Prevalence of key clinical manifestations in MPOX patients during the 2022 outbreak. Based on <xref rid="fig1" ref-type="fig">Figure 1</xref>, fever (57.37%), rash (88.44%), lymphadenopathy (56.68%), and anal pain (20.81%) were among the most frequently reported symptoms during the 2022 MPOX outbreak, highlighting variations in the severity and occurrence of these clinical manifestations.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JTM2024-6688914.003.jpg"/></fig><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Clinical manifestation during 2022 outbreak.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Authors, year, reference</th><th align="center" rowspan="1" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">Study type</th><th align="center" rowspan="1" colspan="1">No. of patients</th><th align="center" rowspan="1" colspan="1">Age median</th><th align="center" rowspan="1" colspan="1">HIV positive (&#8764;%)</th><th align="center" rowspan="1" colspan="1">Skin rash (&#8764;%)</th><th align="center" rowspan="1" colspan="1">Site of skin lesion (&#8764;%)</th><th align="center" rowspan="1" colspan="1">Fever (&#8764;%)</th><th align="center" rowspan="1" colspan="1">Lymph node swelling (&#8764;%)</th><th align="center" rowspan="1" colspan="1">Proctitis or anal pain (&#8764;%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Angelo et al. 2022 [<xref rid="B91" ref-type="bibr">91</xref>]</td><td align="center" rowspan="1" colspan="1">Multicountry</td><td align="center" rowspan="1" colspan="1">Cross-sectional</td><td align="center" rowspan="1" colspan="1">226</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">92 (41)</td><td align="center" rowspan="1" colspan="1">137 (61)</td><td align="center" rowspan="1" colspan="1">Genital (46), perianal (28), trunk (27), face (23), mouse or oral mucosa (20), palms and hands (11)</td><td align="center" rowspan="1" colspan="1">131 (58)</td><td align="center" rowspan="1" colspan="1">82 (36)</td><td align="center" rowspan="1" colspan="1">33 (15)</td></tr><tr><td align="left" rowspan="1" colspan="1">Catal&#224; et al. 2022 [<xref rid="B92" ref-type="bibr">92</xref>]</td><td align="center" rowspan="1" colspan="1">Spain</td><td align="center" rowspan="1" colspan="1">Prospective cross-sectional</td><td align="center" rowspan="1" colspan="1">185</td><td align="center" rowspan="1" colspan="1">38.7</td><td align="center" rowspan="1" colspan="1">78 (42)</td><td align="center" rowspan="1" colspan="1">185 (100)</td><td align="center" rowspan="1" colspan="1">Genital (53) face (39) perianal (34) thorax (25), plantar (12), palmar (6)</td><td align="center" rowspan="1" colspan="1">100 (54)</td><td align="center" rowspan="1" colspan="1">104 (56)</td><td align="center" rowspan="1" colspan="1">40 (22)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gomez-Garberi et al. 2022 [<xref rid="B93" ref-type="bibr">93</xref>]</td><td align="center" rowspan="1" colspan="1">USA<sup>a</sup></td><td align="center" rowspan="1" colspan="1">Prospective observational</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">8/13 (62)</td><td align="center" rowspan="1" colspan="1">14 (100)</td><td align="center" rowspan="1" colspan="1">Anogenital (100), face (50)</td><td align="center" rowspan="1" colspan="1">6 (43)</td><td align="center" rowspan="1" colspan="1">8 (57)</td><td align="center" rowspan="1" colspan="1">1 (7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Girometti et al. 2022 [<xref rid="B94" ref-type="bibr">94</xref>]</td><td align="center" rowspan="1" colspan="1">UK<sup>b</sup></td><td align="center" rowspan="1" colspan="1">Retrospective observational analysis</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">13 (24)</td><td align="center" rowspan="1" colspan="1">54 (100)</td><td align="center" rowspan="1" colspan="1">Genital (61), perianal (44), face (20), limbs (50)</td><td align="center" rowspan="1" colspan="1">31 (57)</td><td align="center" rowspan="1" colspan="1">30 (56)</td><td align="center" rowspan="1" colspan="1">NR<sup>c</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Harrison et al. 2023 [<xref rid="B95" ref-type="bibr">95</xref>]</td><td align="center" rowspan="1" colspan="1">Canada</td><td align="center" rowspan="1" colspan="1">Cohort</td><td align="center" rowspan="1" colspan="1">346</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">314 (91)</td><td align="center" rowspan="1" colspan="1">Genital (46.9), anal (36.7), palmar (26.9), face (34), plantar (16)</td><td align="center" rowspan="1" colspan="1">166 (52)</td><td align="center" rowspan="1" colspan="1">204 (64)</td><td align="center" rowspan="1" colspan="1">102 (33)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hennessee 2022 [<xref rid="B96" ref-type="bibr">96</xref>]</td><td align="center" rowspan="1" colspan="1">USA</td><td align="center" rowspan="1" colspan="1">Case series</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">11.5</td><td align="center" rowspan="1" colspan="1">2 (2)</td><td align="center" rowspan="1" colspan="1">83 (100)</td><td align="center" rowspan="1" colspan="1">Anogenital (40), trunk (55), face and head (41), limbs (31)</td><td align="center" rowspan="1" colspan="1">29 (35)</td><td align="center" rowspan="1" colspan="1">24 (29)</td><td align="center" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Hornuss et al. 2022 [<xref rid="B97" ref-type="bibr">97</xref>]</td><td align="center" rowspan="1" colspan="1">Germany</td><td align="center" rowspan="1" colspan="1">Case series</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">37.7</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">3 (75)</td><td align="center" rowspan="1" colspan="1">Anogenital (100), face (50)</td><td align="center" rowspan="1" colspan="1">2 (50)</td><td align="center" rowspan="1" colspan="1">2 (50)</td><td align="center" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Inigo Martinze et al. 2022 [<xref rid="B98" ref-type="bibr">98</xref>]</td><td align="center" rowspan="1" colspan="1">Spain</td><td align="center" rowspan="1" colspan="1">Cohort</td><td align="center" rowspan="1" colspan="1">508</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">225 (44)</td><td align="center" rowspan="1" colspan="1">498 (98)</td><td align="center" rowspan="1" colspan="1">Anogenital (72.1), face (35.5), palms or plants (24.9)</td><td align="center" rowspan="1" colspan="1">324 (64)</td><td align="center" rowspan="1" colspan="1">311 (61)</td><td align="center" rowspan="1" colspan="1">81 (16)</td></tr><tr><td align="left" rowspan="1" colspan="1">Moschese et al. 2022 [<xref rid="B99" ref-type="bibr">99</xref>]</td><td align="center" rowspan="1" colspan="1">Italy</td><td align="center" rowspan="1" colspan="1">Case series</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">2 (50)</td><td align="center" rowspan="1" colspan="1">3 (75)</td><td align="center" rowspan="1" colspan="1">Anogenital (50), trunk (100), face (100)</td><td align="center" rowspan="1" colspan="1">4 (100)</td><td align="center" rowspan="1" colspan="1">4 (100)</td><td align="center" rowspan="1" colspan="1">1 (25)</td></tr><tr><td align="left" rowspan="1" colspan="1">N&#246;rz et al. 2022 [<xref rid="B100" ref-type="bibr">100</xref>]</td><td align="center" rowspan="1" colspan="1">Germany</td><td align="center" rowspan="1" colspan="1">Case series</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">2 (20)</td><td align="center" rowspan="1" colspan="1">10 (100)</td><td align="center" rowspan="1" colspan="1">Anogenital (90), trunk (40), face (20)</td><td align="center" rowspan="1" colspan="1">3 (30)</td><td align="center" rowspan="1" colspan="1">5 (50)</td><td align="center" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Patal et al. 2022 [<xref rid="B101" ref-type="bibr">101</xref>]</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" rowspan="1" colspan="1">Retrospective observational</td><td align="center" rowspan="1" colspan="1">197</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">70 (35)</td><td align="center" rowspan="1" colspan="1">197 (100)</td><td align="center" rowspan="1" colspan="1">Genital (56.4), anus or perianal (41.6), face (36), trunk (35.5), hands or feet (28.4)</td><td align="center" rowspan="1" colspan="1">122 (62)</td><td align="center" rowspan="1" colspan="1">114 (58)</td><td align="center" rowspan="1" colspan="1">71 (36)</td></tr><tr><td align="left" rowspan="1" colspan="1">Philpott et al. 2022 [<xref rid="B102" ref-type="bibr">102</xref>]</td><td align="center" rowspan="1" colspan="1">USA</td><td align="center" rowspan="1" colspan="1">Cohort</td><td align="center" rowspan="1" colspan="1">1195</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">136/334 (41)</td><td align="center" rowspan="1" colspan="1">1004 (100)</td><td align="center" rowspan="1" colspan="1">Genital (46.4), arms (39.6) perianal (31.3) trunk (21.7) face (38.4), soles or feet (10.7)</td><td align="center" rowspan="1" colspan="1">596 (63)</td><td align="center" rowspan="1" colspan="1">545 (58)</td><td align="center" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">de Sousa et al. 2022 [<xref rid="B76" ref-type="bibr">76</xref>]</td><td align="center" rowspan="1" colspan="1">Portugal</td><td align="center" rowspan="1" colspan="1">Retrospective observational</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">35.1</td><td align="center" rowspan="1" colspan="1">21 (45)</td><td align="center" rowspan="1" colspan="1">47 (100)</td><td align="center" rowspan="1" colspan="1">Genital (63.8), anorectal (46.8), trunk (44.7), face (27.7)</td><td align="center" rowspan="1" colspan="1">25 (53)</td><td align="center" rowspan="1" colspan="1">32 (68)</td><td align="center" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Tarin-Vicente et al. 2022 [<xref rid="B90" ref-type="bibr">90</xref>]</td><td align="center" rowspan="1" colspan="1">Spain</td><td align="center" rowspan="1" colspan="1">Multicenter prospective observational</td><td align="center" rowspan="1" colspan="1">181</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">72 (40)</td><td align="center" rowspan="1" colspan="1">181 (100)</td><td align="center" rowspan="1" colspan="1">Genital (55) perianal (36) trunk (57), hand and feet (60)</td><td align="center" rowspan="1" colspan="1">131 (72)</td><td align="center" rowspan="1" colspan="1">153 (85)</td><td align="center" rowspan="1" colspan="1">45 (25)</td></tr><tr><td align="left" rowspan="1" colspan="1">Thornhill et al. 2022 [<xref rid="B103" ref-type="bibr">103</xref>]</td><td align="center" rowspan="1" colspan="1">Multicountry</td><td align="center" rowspan="1" colspan="1">Case series</td><td align="center" rowspan="1" colspan="1">528</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">218 (41)</td><td align="center" rowspan="1" colspan="1">500 (95)</td><td align="center" rowspan="1" colspan="1">Anogenital (75), face (25), trunk or limbs (55), palms or soles (10)</td><td align="center" rowspan="1" colspan="1">330 (62)</td><td align="center" rowspan="1" colspan="1">295 (56)</td><td align="center" rowspan="1" colspan="1">75 (14)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hoffman et al. 2023 [<xref rid="B104" ref-type="bibr">104</xref>]</td><td align="center" rowspan="1" colspan="1">Germany</td><td align="center" rowspan="1" colspan="1">Multicenter retrospective</td><td align="center" rowspan="1" colspan="1">546</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">256 (47)</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">Genital (49.9), anal (47.9), trunk or extremities (37.5)</td><td align="center" rowspan="1" colspan="1">272 (53)</td><td align="center" rowspan="1" colspan="1">213 (43)</td><td align="center" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Mailhe et al. 2023 [<xref rid="B77" ref-type="bibr">77</xref>]</td><td align="center" rowspan="1" colspan="1">France</td><td align="center" rowspan="1" colspan="1">Cohort</td><td align="center" rowspan="1" colspan="1">264</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">73 (29)</td><td align="center" rowspan="1" colspan="1">258 (98)</td><td align="center" rowspan="1" colspan="1">Genital (54), perianal (40), face (35), limbs (48)</td><td align="center" rowspan="1" colspan="1">171 (68)</td><td align="center" rowspan="1" colspan="1">174 (69)</td><td align="center" rowspan="1" colspan="1">45 (18)</td></tr><tr><td align="left" rowspan="1" colspan="1">van Ewijk et al. 2023 [<xref rid="B105" ref-type="bibr">105</xref>]</td><td align="center" rowspan="1" colspan="1">The Netherlands</td><td align="center" rowspan="1" colspan="1">Epidemiological surveillance</td><td align="center" rowspan="1" colspan="1">1000</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">187 (21)</td><td align="center" rowspan="1" colspan="1">914 (92)</td><td align="center" rowspan="1" colspan="1">Genital (51) perianal (33) face (34) trunk (38), limbs (51)</td><td align="center" rowspan="1" colspan="1">521 (53)</td><td align="center" rowspan="1" colspan="1">371 (37)</td><td align="center" rowspan="1" colspan="1">178 (18)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hoffman, Jessen, and Boesecke, 2022 [<xref rid="B106" ref-type="bibr">106</xref>]</td><td align="center" rowspan="1" colspan="1">Germany</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">301</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">141 (47)</td><td align="center" rowspan="1" colspan="1">276/301 (99)</td><td align="center" rowspan="1" colspan="1">Genital (49), anal (51), oral, perioral, head (24), trunk (42)</td><td align="center" rowspan="1" colspan="1">168/274 (61)</td><td align="center" rowspan="1" colspan="1">116/263 (44)</td><td align="center" rowspan="1" colspan="1">NR</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic toggle="yes">Note:</italic> Clinical manifestations of MPOX during the 2022 outbreak across different studies. This table summarizes the prevalence of clinical manifestations, including proctitis, fever, lymph node swelling, and skin lesions, as reported in various studies during the 2022 MPOX outbreak.</p></fn><fn><p>
<sup>a</sup>United States of America.</p></fn><fn><p>
<sup>b</sup>United Kingdom.</p></fn><fn><p>
<sup>c</sup>Not reported.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tab2" orientation="portrait"><label>Table 2</label><caption><p>Comparison of characteristics of different therapeutic agents for MPOX infection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">Tecovirimat</th><th align="center" rowspan="1" colspan="1">Brincidofovir</th><th align="center" rowspan="1" colspan="1">Cidofovir</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Mechanism of action</td><td align="center" rowspan="1" colspan="1">Inhibits the viral envelope protein VP37, preventing the release of mature virus particles from infected cells, thus limiting viral spread</td><td align="center" rowspan="1" colspan="1">DNA polymerase inhibitor</td><td align="center" rowspan="1" colspan="1">DNA polymerase inhibitor</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>
<sub>(1/2)</sub>
</td><td align="center" rowspan="1" colspan="1">18&#8211;26&#8201;h</td><td align="center" rowspan="1" colspan="1">19.3&#8201;h (CDV-pp: 133&#8201;h)</td><td align="center" rowspan="1" colspan="1">3.2&#8211;4.4&#8201;h</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein binding</td><td align="center" rowspan="1" colspan="1">77%&#8211;82%</td><td align="center" rowspan="1" colspan="1">&gt; 99.9%</td><td align="center" rowspan="1" colspan="1">&lt; 6%</td></tr><tr><td align="left" rowspan="1" colspan="1">Elimination</td><td align="center" rowspan="1" colspan="1">Less than 1% exsert in urine as unchanged drug; fecal elimination</td><td align="center" rowspan="1" colspan="1">More than 50% excreted in urine and 40% in feces after metabolism</td><td align="center" rowspan="1" colspan="1">70%&#8211;85% excreted in urine unchanged</td></tr><tr><td align="left" rowspan="1" colspan="1">Significant adverse drug effect</td><td align="center" rowspan="1" colspan="1">Headache, abdominal pain, nausea, vomiting, oral dryness, hypersensitivity</td><td align="center" rowspan="1" colspan="1">Nausea, diarrhea, vomiting, abdominal pain, and bilirubin and transaminase elevation</td><td align="center" rowspan="1" colspan="1">Neutropenia, nephrotoxicity, decrease in ocular pressure</td></tr><tr><td align="left" rowspan="1" colspan="1">Pharmacokinetic properties and administration</td><td align="center" rowspan="1" colspan="1">Taking 30&#8201;min after a moderate-to-high fat meal increases absorption. For children 13&#8201;kg and above, the capsule can be opened and mixed with milk or soft food.</td><td align="center" rowspan="1" colspan="1">The tablet should be taken on an empty stomach or with a low-fat meal. Shake the suspension form before taking. It can be given through an NG/G tube</td><td align="center" rowspan="1" colspan="1">Dilute in 100&#8201;mL NS and infuse over 1&#8201;h WITH probenecid: 2&#8201;g 3&#8201;h before CVD, 1&#8201;g at 2- and 8&#8201;h postcompletion. Administer 1L NS with each CVD infusion over 1-2&#8201;h before infusion. Consider additional NS infusion at the start or after CVD over 1-3&#8201;h if tolerable</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal dose adjustment</td><td align="center" rowspan="1" colspan="1">No dose adjustment is needed for capsules; IV form is contraindication in CrCl &lt; 30&#8201;mL/minute</td><td align="center" rowspan="1" colspan="1">Non</td><td align="center" rowspan="1" colspan="1">Reduce maintenance dose from 5&#8201;mg/kg to 3&#8201;mg/kg if SCr increases 0.3&#8211;0.4&#8201;mg/dL from baseline and discontinue if&#8201;&#8805;&#8201;0.5&#8201;mg/dL above baseline or development of &#8805; 3+ proteinuria</td></tr><tr><td align="left" rowspan="1" colspan="1">Use in pregnancy</td><td align="center" rowspan="1" colspan="1">No fetal or embryo toxicity observed in animal studies</td><td align="center" rowspan="1" colspan="1">Fetal harm and embryo toxicity were observed in rats and rabbits. Pregnancy tests should be done before administration, and contraceptives should be used for 2&#8201;months after the last dose</td><td align="center" rowspan="1" colspan="1">Not recommended in pregnancy</td></tr><tr><td align="left" rowspan="1" colspan="1">Use in lactation</td><td align="center" rowspan="1" colspan="1">Presenting in milk is unknown; tecovirimat is preferred antiviral in lactating patients</td><td align="center" rowspan="1" colspan="1">It is not recommended as an alternative therapy in MPOX lactating patient</td><td align="center" rowspan="1" colspan="1">Not recommended in lactation</td></tr><tr><td align="left" rowspan="1" colspan="1">Metabolism</td><td align="center" rowspan="1" colspan="1">CYP2C19, CYP2C8 weak inhibitor; CYP3A4 weak inducer</td><td align="center" rowspan="1" colspan="1">MRP2 inhibitor</td><td align="center" rowspan="1" colspan="1">MRP2 inhibitor</td></tr><tr><td align="left" rowspan="1" colspan="1">Safety profile</td><td align="center" rowspan="1" colspan="1">Mild side effects (headache, nausea). Safe for pregnancy/lactation. Avoid IV use in severe renal impairment. Preferred for immunocompromised patients</td><td align="center" rowspan="1" colspan="1">Risk of hepatotoxicity (elevated liver enzymes). Contraindicated in pregnancy/lactation. Requires liver function monitoring. Avoid severe liver dysfunction</td><td align="center" rowspan="1" colspan="1">Significant nephrotoxicity. Requires hydration and probenecid coadministration. Contraindicated in severe renal impairment, pregnancy, and lactation. Close renal monitoring essential</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic toggle="yes">Note:</italic> Comparative characteristics and safety profiles of therapeutic agents for MPOX. This table provides a side-by-side comparison of key therapeutic agents for MPOX, including their mechanisms of action, half-lives, significant adverse effects, and safety profiles for specific populations.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>